Stockwinners Market Radar for June 07, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EDT Cathie Wood's ARK Investment bought 3K shares of Tesla today

20:13 EDT Cathie Wood's ARK Investment bought 59K shares of Roku today

20:04 EDT NRx Pharmaceuticals names Seth Van Voorhees as CFO - NRx Pharmaceuticals "announced that the company's board appointed Seth Van Voorhees, Ph.D. as CFO and Treasurer effective June 13, 2022. Dr. Van Voorhees most recently served as CFO of PDS Biotechnology during which he completed several financing transactions in 2021."

19:59 EDT Ball Corp. recommends rejection of below-market mini-tender by TRC Capital - Ball Corp "received notice today of an unsolicited mini-tender offer by TRC Capital Corporation to purchase up to 2.0M Ball common shares, representing approximately .63% of the company's outstanding shares. TRC's offer price of $70.50 per share in cash is approximately 2.9% lower than the $72.51 closing price of Ball common shares on June 2, 2022, the last closing price prior to commencement of the offer. Ball Corporation does not recommend or endorse TRC's unsolicited below-market mini-tender offer and recommends that shareholders not tender their shares because the offer is at a price significantly below the current market price of Ball common shares."

18:50 EDT Northern Oil and Gas raises 2022 annual production view to 73,00-77,000 Boe/pd - Prior view was 71,000-76,000 Boe per day. NOG anticipates, pro forma for the transactions and at current strip pricing, increasing its Free Cash Flow target for 2022 from greater than$425M to greater than$500M. NOG anticipates a Q4:22 exit rate above the high-end of the revised 2022 annual production guidance range.

18:48 EDT Northern Oil and Gas raises 2022 CapEx view to $405M-$470M from $350M-$415M

18:42 EDT Vincerx Pharma Chief Medical Officer to depart - In a regulatory filing, Vincerx Pharma stated that in connection with its Strategic Plan calling for 33% staff cuts disclosed yesterday, Hermes Garban, M.D., Ph.D., will depart from his role as the company's Chief Medical Officer on or before August 6, 2022.

18:23 EDT Lyft President, co-founder: We are seeing good signs of momentum - In an interview on CNBC's Mad Money, John Zimmer said the number of rides a driver takes is up over 20% since 2019. The commute is about 30% of total rides, in-line with pre-pandemic, he added. Many of the company's recent investments can be controlled based on the market dynamics, he noted. Zimmer is "confident" in the outlook ahead, and is seeing "positive signs" in the marketplace.

17:59 EDT Supernus' Huperzine granted FDA orphan designation - Supernus' Huperzine was granted FDA orphan designation as a treatment of SCN8A Developmental and Epileptic Encephalopathy, according to a post to the agency's website. Reference Link

17:55 EDT Novavax jumps 22% to $57.85 after FDA granted EUA for COVID-19 vaccine

17:30 EDT Novavax trading resumes

17:10 EDT Novavax says FDA panel recommends EUA for COVID-19 vaccine - Novavax announced the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee voted 21 to 0, with one abstention, to recommend that the FDA grant Emergency Use Authorization for the Novavax COVID-19 vaccine for individuals aged 18 years and over. "The advisory committee's positive recommendation acknowledges the strength of our data and the importance of a protein-based COVID-19 vaccine developed using an innovative approach to traditional vaccine technology," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "In today's VRBPAC meeting, we heard the overwhelming support for our vaccine from physicians, healthcare organizations, and consumers who are eagerly anticipating a protein-based vaccine option. Consistent with submissions to regulatory authorities worldwide, we have already submitted an amendment with updated manufacturing information for the EUA to the FDA for review. We look forward to collaborating with the FDA as it makes its final decision." The VRBPAC considered data from the pivotal Phase 3 clinical trial, PREVENT-19, which enrolled approximately 30,000 participants aged 18 years and older in the U.S. and Mexico and was published in the New England Journal of Medicine. In the trial, the Novavax COVID-19 vaccine demonstrated 90.4% efficacy with a reassuring safety profile. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups. The most common adverse reactions observed during the trial were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise. The data showed that overall the rate of myocarditis was balanced between the vaccine and placebo arms and in the post-crossover portions of Novavax trials the observed cases were all within the expected rate.

17:03 EDT Casey's General Stores raises quarterly dividend 9% to 38c per share - The dividend is payable August 15 to shareholders of record on August 1.

17:00 EDT DBV Technologies trading resumes

16:53 EDT Symbotic completes combination with SPAC SVF Investment - Symbotic announced the completion of its business combination with SVF Investment (SVFC), a special purpose acquisition company sponsored by an affiliate of SoftBank Investment Advisers, to become a publicly traded company. The combined company will operate as "Symbotic Inc.," and its Class A common stock expects to trade on The Nasdaq Stock Market under the ticker symbol "SYM" on June 8. The business combination was approved at a special meeting of SVFC shareholders held on June 3, As a result of the transaction, the combined company received additional growth capital to supplement its existing $363M of combined cash on the balance sheet as of March 26, and proceeds from a May 20, warrant exercise. This will enable Symbotic to accelerate its growth, expand into new verticals, and progress toward its financial targets. With an existing industry-leading $11-plus billion in contracted orders, Symbotic has proven to customers the power of its technology and ability to scale quickly. "Our vision at Symbotic has always been to reinvent the supply chain with artificial intelligence and robotics - transforming the distribution network into a strategic asset," said Rick Cohen, Chairman of the Board of Directors and President of Symbotic. "As a leading robotics innovator, I look forward to scaling Symbotic to meet the incredible demands and opportunities of the global supply chain. We are proud to be affiliated with the SoftBank (SFTBY) team and are eager to begin this next chapter together." "We believe Symbotic is at the forefront of a more than $350B market opportunity to reinvent warehouse automation and reshape the global supply chain," said Vikas J. Parekh, Managing Partner for SoftBank Investment Advisers and a member of Symbotic's Board of Directors. "With its revolutionary A.I.-enabled technology platform and deep relationships with some the world's largest companies, Symbotic is already making the right strategic investment decisions and we believe it is well positioned to achieve long-term success." Michael J. Loparco, Symbotic CEO, will continue to lead the combined company through its next phase of growth, innovation, and expansion, alongside Rick Cohen, Chairman of the Board of Directors and President of Symbotic.

16:46 EDT Regeneron, Sanofi: FDA approves Dupixent for children aged 6 months to 5 years - Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. FDA has approved Dupixent for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regulatory filings for this age group are underway by the European Medicines Agency and regulatory authorities in additional countries.

16:38 EDT Goodyear recalls over 170,000 tires sold for use on trucks, RVs - Goodyear is recalling more than 170,000 tires that were produced between 1996 and 2003 and sold for use on trucks and recreational vehicles. The National Highway Traffic Safety Administration found that these tires experienced a high rate of failure on RVs when compared to similar tires. Tire failure at highway speeds can lead to serious injury or death. The recall specifically applies to G159 tires size 275/70R22.5, commonly found on RVs. While these tires are no longer being produced, some RV owners may have the tires on their vehicle, or set aside as a spare, and do not know. NHTSA urges anyone who owns, rents, or uses an RV or truck with 22.5-inch rims to ensure these tires are not in use on their vehicle. Despite being discontinued, it is possible that these tires can be found for purchase on online marketplaces. It is illegal under federal law to sell recalled tires or other motor vehicle equipment. Reference Link

16:32 EDT Illinois American Water acquires Village of Hardin water, wastewater systems - Illinois American Water, a subsidiary of American Water, announced that it has completed the acquisition of the Village of Hardin water and wastewater systems. The newly acquired system adds approximately 435 water and 405 wastewater customers to the company's southern Illinois service area. The Village of Hardin is located near Illinois American Water's Jerseyville operations. "Our team is excited and ready to serve the Village of Hardin as we expand our footprint across our Southern Illinois service area," said Justin Ladner, President of Illinois American Water. "Since 2020 we have had the privilege to add over 26,000 new customer connections and partner with over 10 communities across Illinois through acquisitions. We are excited to include Village of Hardin to our customer base." The Village of Hardin voted in favor of the sale in May 2021. The Illinois Commerce Commission recently approved the sale for $3.3M.

16:30 EDT EZGO Technologies receives Nasdaq notification over minimum bid price - EZGO Technologies Ltd. announced that the Company had received a notification letter dated June 3, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC, notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's ordinary shares, par value $0.001 per share was below $1.00 per share for a period of 30 consecutive business days. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the Company's Ordinary Shares, which will continue to trade uninterrupted on Nasdaq under the ticker "EZGO".

16:25 EDT Smartsheet falls 6.6% to $37.97 after Q1 results and guidance

16:20 EDT Pzena Investment reports AUM as of May 31 $50.7B - Pzena Investment Management reported its preliminary assets under management as of May 31 .

16:19 EDT Core & Main signs agreement to acquire Earthsavers Erosion Control - Core & Main has entered into a definitive agreement to acquire substantially all of the assets of Earthsavers Erosion Control, LLC, a full-service provider of geosynthetics products. "Earthsavers Erosion Control has a strong presence in their market and a loyal customer base that asks for their products by name. This strategic acquisition will provide additional capacity and will allow us to enhance Core & Main's erosion control expertise to further serve our customers throughout the western region of the U.S.," said Steve LeClair, chief executive officer of Core & Main.

16:15 EDT Limoneira expects 'stronger position' in retail food, club grocery in FY22 - The company said, "The COVID-19 pandemic continues to affect the Company's food service business and industry logistics on a global basis. The Company expects it will experience improving results in fiscal year 2022 compared to fiscal year 2021 due to its stronger position in retail food and club grocery and growing brokered fruit revenues. The resurgence of COVID-19 during the first half of this year pressured lemon prices. As food service and export markets recover, the Company expects lemon prices to increase in the second half of fiscal year 2022 compared to the prior year period. The Company continues to expect fresh lemon volumes to be in the range of 4.5 million to 5.0 million cartons for fiscal year 2022. The Company expects avocado volumes to be in the range of 6.0 million to 7.0 million pounds for fiscal year 2022 and strong profitability for the third quarter of fiscal year 2022."

16:14 EDT System1 set to join Russell 2000, Russell 3000 Indexes - System1, Inc. is set to join the broad-market Russell 2000 and Russell 3000 Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022, according to a preliminary list of additions posted June 3, 2022. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 6, 2022, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in either the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Michael Blend, System1's Chief Executive Officer and Co-Founder, stated, "We are very pleased to be included in the Russell indexes, marking another significant milestone for System1 in what has been a truly noteworthy and transformative year."

16:13 EDT Ontrak Health, Eleos announces AI integration partnership - Ontrak Health announced a partnership to integrate their artificial intelligence platforms to support member care and reduce administrative tasks. Ontrak's proprietary AI-supported Advanced Engagement System identifies, engages, and provides treatment for the most vulnerable members of the behavioral health population to achieve improved and sustained clinical outcomes. Eleos' voice-to-insights AI technology will be integrated into the work of Ontrak's evidence-based care model and its growing nationwide care teams, including mental health providers. "We are pleased to be working with Ontrak Health, a long-time leader in behavioral health, to support its efforts to provide personalized effective care to its members," said Alon Joffe, CEO and Co-Founder, Eleos Health. "Our aim is to enable patient-facing teams to focus on treatment by reducing documentation time and provide actionable insights to continually improve care."

16:11 EDT Concord Acquisition to extend period to consummate initial business combination - Concord Acquisition Corp announced that Circle Internet Financial Limited, a private company limited by shares incorporated in Ireland has deposited $2,760,000 into the company's trust account for its public stockholders, representing 10c per public unit sold in the company's initial public offering, which enables the company to extend the period of time it has to consummate its initial business combination by six months from June 10 to December 10, as permitted under the company's amended and restated certificate of incorporation.

16:09 EDT Eiger BioPharmaceuticals enters $5M stock purchase agreement with Innovatus - Eiger BioPharmaceuticals announced that it has entered into a term loan agreement with an affiliate of Innovatus Capital Partners for up to $75M and a stock purchase agreement for Innovatus to purchase $5M of the company's stock. This loan facility and stock sale provide for the refinancing of the company's existing debt and will support the continued development and commercialization of Eiger's late-stage pipeline.

16:07 EDT 3D Systems names David Shulkin to Medical Advisory Board - 3D Systems "announced the appointment of David J. Shulkin, MD, former United States Secretary of Veterans Affairs, to the company's recently established Medical Advisory Board. The primary mission of the MAB is to provide strategic input, guidance, and recommendations for the company's expanding efforts in regenerative medicine."

16:07 EDT Nikola urges stockholders to vote "FOR" each proposal at annual meeting - Nikola released a letter to stockholders in connection with its 2022 Annual Meeting of Stockholders, which is scheduled for June 30 The letter urges stockholders to vote "FOR" each proposal, including a proposal to increase the number of authorized shares of the Company's common stock, as described in Nikola's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 2.

16:06 EDT Teradyne names Greg Smith as President - Teradyne announced that Greg Smith has been appointed President of Teradyne, effective July 1, 2022. Mark Jagiela will continue as the company's CEO.

16:02 EDT Alvotech, Oaktree announce shareholder approval of business combination - Alvotech (ALVO) and Oaktree Acquisition Corp. II (OACB) announced that their previously announced business combination between Alvotech S.A., OACB and the legal entity named Alvotech, previously named Alvotech Lux Holdings S.A.S., with Alvotech as the surviving entity was approved by OACB shareholders at an Extraordinary General Meeting on June 7, 2022. It is anticipated that the Business Combination will close on or about June 15, 2022, subject to the satisfaction of all other applicable closing conditions. The ordinary shares of Alvotech are expected to trade under the new ticker symbol "ALVO" on The Nasdaq Stock Market in New York and The Nasdaq First North Growth Market in Reykjavik and the warrants of Alvotech are expected to trade on The Nasdaq Stock Market in New York under the new ticker symbol "ALVOW."

15:32 EDT L3Harris team selected for $205M SPEIR contract from U.S. Navy - A team led by L3Harris Technologies (LHX) has been selected to provide the Shipboard Panoramic Electro-Optic/Infrared, or SPEIR, system to the U.S. Navy that will provide improved fleet protection. The initial $205M contract has a potential value of $593M if all options are exercised through March 2031, the company stated. The team includes Lockheed Martin (LMT) and BAE Systems (BAESY) and will provide an L3Harris solution known as SPATIAL that provides a scalable 360-degree EO/IR passive automatic detection and tracking solution, enhancing combat systems and navigation capabilities to the U.S. Navy.

14:48 EDT Prescience Point calls on MiMedx to release annual meeting voting results - Prescience Point Capital Management LLC, an investment firm that beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group, has issued a statement, calling upon the company to report the preliminary results of its annual meeting of shareholders, held earlier Tuesday. Eiad Asbahi, Founder and Managing Partner of Prescience Point, stated: "We find it extremely suspect that, while MiMedx stated during the annual meeting proceedings that director nominees Phyllis Gardner and James Bierman were re-elected, the Company has not taken the usual step of promptly releasing the preliminary voting results to all shareholders. In the interest of full transparency, we call upon MiMedx to immediately release the preliminary voting results of the annual meeting, so that the public can see whether the Board and management have lost the confidence of the Company's shareholder base. We believe MiMedx is delaying the release of the preliminary vote tally because these results will reveal widespread shareholder discontent. Based on our discussions with shareholders after the annual meeting, we believe the vote tally will show that a majority of the shares held by non-affiliated, non-institutional holders were voted AGAINST the Company's incumbent director nominees, and AGAINST the Company's executive compensation-based "say-on-pay" proposal. If, as we believe, the unaffiliated portion of MiMedx's shareholder base is truly unified in its discontent with the status quo, we are hopeful that this will be the catalyst for the Board and management to begin to operate MiMedx in the best interests of ALL shareholders, and put the Company on a more positive and constructive path."

13:55 EDT Global growth to fall to 2.9% in 2022 from 5.7% in 2021, World Bank says - "Compounding the damage from the COVID-19 pandemic, the Russian invasion of Ukraine has magnified the slowdown in the global economy, which is entering what could become a protracted period of feeble growth and elevated inflation, according to the World Bank's latest Global Economic Prospects report. This raises the risk of stagflation, with potentially harmful consequences for middle- and low-income economies alike. Global growth is expected to slump from 5.7% in 2021 to 2.9% in 2022- significantly lower than 4.1% that was anticipated in January. It is expected to hover around that pace over 2023-24, as the war in Ukraine disrupts activity, investment, and trade in the near term, pent-up demand fades, and fiscal and monetary policy accommodation is withdrawn. As a result of the damage from the pandemic and the war, the level of per capita income in developing economies this year will be nearly 5 percent below its pre-pandemic trend."The war in Ukraine, lockdowns in China, supply-chain disruptions, and the risk of stagflation are hammering growth. For many countries, recession will be hard to avoid," said World Bank President David Malpass. "Markets look forward, so it is urgent to encourage production and avoid trade restrictions. Changes in fiscal, monetary, climate and debt policy are needed to counter capital misallocation and inequality," said the World Bank in a statement. Reference Link

13:25 EDT FTC announces inquiry into pharmacy benefit managers - The Federal Trade Commission announced that it will launch an inquiry into the "prescription drug middleman industry," requiring the six largest pharmacy benefit managers to provide information and records regarding their business practices. The agency's inquiry will scrutinize the impact of vertically integrated pharmacy benefit managers on the access and affordability of prescription drugs. As part of this inquiry, the FTC will send compulsory orders to CVS Caremark (CVS); Cigna's (CI) Express Scripts, Inc.; UnitedHealth's (UNH) OptumRx, Inc.; Humana Inc. (HUM); Prime Therapeutics LLC; and MedImpact Healthcare Systems, the Commission stated. The Commission's inquiry will examine pharmacy benefit managers' role at the center of the U.S. pharmaceutical system. Pharmacy benefit managers are the middlemen who are hired to negotiate rebates and fees with drug manufacturers, create drug formularies and surrounding policies, and reimburse pharmacies for patients' prescriptions. "Although many people have never heard of pharmacy benefit managers, these powerful middlemen have enormous influence over the U.S. prescription drug system," said Federal Trade Commission Chair Lina M. Khan. "This study will shine a light on these companies' practices and their impact on pharmacies, payers, doctors, and patients."

13:08 EDT Nvidia has selected Sapphire Rapids to be the CPU for Hopper, says Huang - Nvidia CEO Jensen Huang is speaking at the BofA Global Technology Conference.

12:56 EDT Immatics, Editas Medicine announce strategic collaboration and licensing pact - Immatics (IMTX) and Editas Medicine (EDIT) earlier today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine's CRISPR technology and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institute's Cas9 patent estates and Broad Institute's Cas12a patent estate for human medicines. "Engineered cell therapies have the potential to significantly impact the treatment paradigm for cancer, and our partnership with the esteemed team at Editas Medicine will provide us with further versatility and flexibility in how we engineer our ACTallo cell therapies based on a specific tumor target. It has always been our focus to deliver innovative science to cancer patients and this collaboration with Editas Medicine will enable us to access CRISPR technologies and apply them to our off-the-shelf gamma-delta T cell platform," said Rainer Kramer, Ph.D., Chief Business Officer, Immatics. Under the terms of the agreement, Editas Medicine will be eligible to receive an undisclosed upfront cash payment as well as additional milestone payments based on development, regulatory, and commercial milestones. In addition, Immatics will pay royalties on future net sales on any products that may result from this collaboration.

12:22 EDT PMV Pharmaceuticals sinks 24% to $10.55 after Phase I solid tumor data

12:02 EDT PMV Pharmaceuticals presents initial PC14586 Phase I data - PMV Pharmaceuticals announced that preliminary results from the ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors harboring a p53 Y220C mutation demonstrated anti-tumor efficacy across multiple tumor types with an acceptable safety profile. PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors. The most common treatment-emergent adverse events included nausea, vomiting, AST increase, ALT increase, anemia, blood creatinine increase, and fatigue. The maximum tolerated dose was reached at 1500 mg twice daily. Enrollment at doses below the MTD is ongoing to support the determination of a recommended Phase 2 dose. ORR assessed by investigators according to RECIST v1.1 was 32% in patients receiving an initial total daily dose of 1150 mg and above. Of the 8 responding patients, 6 have confirmed partial responses and 2 have unconfirmed partial responses, pending confirmation. ORR was 24% across all dose cohorts. Responses were observed across six distinct tumor types including breast, endometrial, prostate, pancreatic, ovarian, and small cell lung cancer. Best Response of stable disease or partial response was observed in 19/25 patients at doses greater than or equal to1150 mg. "These encouraging Phase 1 safety and preliminary efficacy data provide proof of concept for PC14586 as monotherapy to selectively reactivate p53 across multiple tumor types," said Leila Alland, M.D., Chief Medical Officer of PMV Pharma. "We look forward to completing the Phase 1 portion of the PYNNACLE study in the second half of this year and initiating the potentially pivotal Phase 2 portion of the study early in 2023."

12:00 EDT Rev Group falls -17.2% - Rev Group is down -17.2%, or -$2.09 to $10.08.

12:00 EDT Citizens rises 11.4% - Citizens is up 11.4%, or 38c to $3.72.

12:00 EDT Eve Holding rises 17.3% - Eve Holding is up 17.3%, or $1.31 to $8.89.

11:54 EDT PMV Pharmaceuticals trading halted, volatility trading pause

11:53 EDT PayPal users can now transfer and receive bitcoin, ethereum - Starting today, PayPal supports the native transfer of cryptocurrencies between PayPal and other wallets and exchanges, the company said in a statement. "This feature has been consistently ranked by users as one of the most requested enhancements since we began offering the purchase of crypto on our platform," it added. Available now to select U.S. users and rolling out to all eligible U.S. customers in the coming weeks, thw new functionality lets PayPal customers: Transfer supported coins into PayPal; Move crypto from PayPal to external crypto addresses including exchanges and hardware wallets; Send crypto to family and friends on PayPal in seconds, with no fees or network charges to send or receive. PayPal said it has also been granted a full Bitlicense by the New York Department of Financial Services, becoming the first company to convert a conditional Bitlicense into a full Bitlicense. Reference Link

11:09 EDT Adobe expands partnership with Home Depot - Adobe announced it has expanded its partnership with The Home Depot to enhance the customer experience. The company said,"The Home Depot has led the way in bridging the online and offline shopping experience. As part of the company's interconnected retail strategy, a seamless experience extends across e-commerce, an award-winning mobile app and in-store services such as pickup lockers and an in-app product locator. With so many touchpoints, the Adobe partnership will provide comprehensive insights into the customer journey. This will enable The Home Depot to optimize experiences across channels while refining marketing investments."

11:02 EDT Uber Freight, Waymo Via partner to accelerate future of logistics - Uber Freight and Waymo Via announced a long-term strategic partnership to connect their technologies and deploy autonomous trucks at scale on the Uber Freight network. The companies said, "This partnership brings together the power of Waymo's autonomous driving technology with the scale of Uber Freight's network and leading marketplace technology, unlocking a roadmap for the thoughtful and safe implementation of autonomous trucks on America's roads. This agreement is an important milestone that includes a deep product integration and long-term collaboration roadmap that involves building the tools and infrastructure specific to the successful deployment of autonomous trucks for Uber Freight's shipper and carrier customers. Carriers that purchase trucks equipped with the Waymo Driver in the future will be able to opt-in to Uber Freight's marketplace through user-friendly applications that enable them to seamlessly deploy their autonomous assets on the Uber Freight network." As part of the long-term agreement, Waymo Via intends to reserve billions of miles of its goods-only capacity for the Uber Freight network.

10:59 EDT Janssen announces 29.2% response rate in Phase 2 solid tumor study - Janssen Pharmaceutical of Johnson & Johnson announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of Bakversa, a fibroblast growth factor receptor kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. The primary endpoint of the RAGNAR study is the overall response rate as assessed by an independent review committee. At the data cutoff, independent review committee assessed an ORR of 29.2% and a disease control rate of 72.5% for the overall tumor-agnostic patient population. Investigators observed responses in 14 distinct tumor types. This included responses in "hard-to-treat malignancies" such as salivary gland cancer, pancreatic cancer and glioblastoma, Janssen said in a statement. Investigators also observed an overall 7.1-month median duration of response. At the data cutoff, 51.1 %, or 24 patients who had responded to treatment continued to show a response. The primary analysis for all patients treated in this RAGNAR cohort, known as the broad panel cohort, is anticipated later this year. The discontinuation rate due to drug-related adverse events was 7.3%.

10:51 EDT Synchronoss settles with SEC over 'accounting improprieties' for 12.5M - The Securities and Exchange Commission charged Synchronoss Technologies and seven senior employees, including the former CFO, in connection with their roles related to "accounting improprieties" that ran from 2013 to 2017. In addition, the company's founder and former CEO, Stephen Waldis, while not charged with misconduct, agreed to reimburse the company for more than $1.3M in stock sale profits and bonuses as well as to return previously granted shares of company stock. The SEC filed a complaint in federal district court in Manhattan against former CFO Karen Rosenberger and former Controller Joanna Lanni. Among other things, the SEC's complaint alleges that Rosenberger engaged in fraud through her role in improperly recognizing revenue on multiple transactions and that she also misled Synchronoss's auditor about multiple transactions. The SEC alleges Lanni was involved in improper accounting for one transaction. Without admitting or denying the SEC's findings, Synchronoss agreed to cease and desist from violating Section 10(b) of the Securities Exchange Act of 1934 and other provisions of the securities laws, and to pay a civil penalty of $12.5M. Clayton Thomas, Marc Bandini, Daniel Ives, former senior employees of the company, along with current employee, John Murdock, settled charges from their participation in at least one side letter agreement that concealed the revenue that Synchronoss recognized upfront was in fact contingent on future events and to pay civil penalties ranging from $15,000 to $90,000.

10:46 EDT Mawson Infrastructure to become 33% shareholder of TDI - Mawson Infrastructure Group announced that it will become a 33% shareholder in Tasmania Data Infrastructure. TDI is developing a large-scale, 100% renewable energy Bitcoin Mining facility at the Que River Mine Site in Tasmania, Australia with up to 35 megawatts of energy infrastructure available for Bitcoin Mining in Q3, 2022. Mawson will also have the right to host up to 10MW of its own Bitcoin Mining infrastructure at the site. The site has potential expansion capacity in excess of 100 megawatts, subject to infrastructure upgrades over time. Mawson has exchanged approximately 1975 ASIC Bitcoin Miners for a 33% equity holding in TDI and will provide a license for TDI to utilize Mawson's Modular Data Center and associated technology. The sale of the ASIC Bitcoin Miners reflects Mawson's strategy to continually cycle and upgrade our overall fleet of equipment, with the sale to be reflected in the second quarter 2022 financial results. The Que River Mine Site covers a total area of approximately 300 hectares, is located directly adjacent to TasNetworks Que substation, and is in close proximity to two large-scale transmission lines servicing the northwest part of Tasmania. The site is powered by 100% renewable energy, has an existing 40MVA substation with significant additional power availability, advanced installed communication infrastructure and sits atop a landholding of 30 hectares, providing ample space for future Modular Date Center expansion.

10:17 EDT New Relic up 6% to $50.59 after reaching agreement with Jana

10:04 EDT JetBlue Vacations named official travel partner of Inter Miami CF - JetBlue announced its new partnership becoming the Official Travel Partner of the Major League Soccer team, Inter Miami CF. The new partnership launches during the 2022 season with eight in-match features that will offer lucky fans the opportunity to win a JetBlue Vacations travel credit. The new agreement marks JetBlue Travel Products' first sponsorship of a major league sports team and solidifies its commitment to the South Florida community. Throughout the remainder of the 2022 season, the agreement will allow JetBlue Vacations to engage with Inter Miami fans and travelers alike through integrated marketing efforts, showing why booking through JetBlue Vacations is the best value for money a customer can get. As the Official Travel Partner of Inter Miami, JetBlue Vacations' partnership will include joint marketing promotions and advertising. Elements will include online advertising, email marketing, InterMiamiCF.com logo placement and video features, as well as one sweepstakes that will offer a travel package for one Inter Miami CF supporter plus one guest to a future away match. JetBlue Vacations will also provide suggested travel packages to South Florida, giving customers access to uniquely discounted flights and hotels. Together, JetBlue Vacations and Inter Miami will work together to connect the South Florida community with the rest of the country.

10:01 EDT GridMarket announces EV transition initiative with Ideanomics - GridMarket is thrilled to announce that Coast Counties Peterbilt will be deploying solar, battery storage, and EV charging stations at an initial four sites across the state. The projects were facilitated and optimized through the GridMarket Platform. Ideanomics Energy was selected through GridMarket's competitive process and marketplace to implement and operate the projects.

10:00 EDT Boxed falls -16.2% - Boxed is down -16.2%, or -89c to $4.62.

10:00 EDT Forge Global rises 8.8% - Forge Global is up 8.8%, or $1.19 to $14.78.

10:00 EDT Peabody Energy rises 10.7% - Peabody Energy is up 10.7%, or $2.79 to $28.86.

09:47 EDT DHI Group falls -11.0% - DHI Group is down -11.0%, or -74c to $5.98.

09:47 EDT Boxed falls -20.7% - Boxed is down -20.7%, or -$1.14 to $4.37.

09:47 EDT United Natural Foods rises 8.7% - United Natural Foods is up 8.7%, or $3.89 to $48.80.

09:46 EDT Entrada Therapeutics Inc trading resumes

09:39 EDT Affirm announces resignation of chief commercial officer Silvija Martincevic - In a regulatory filing, Affirm said that on May 31, Silvija Martincevic notified the company of her decision to resign as Chief Commercial Officer as of June 30, 2022. In connection with Martincevic's resignation, on June 6, 2022, Ms. Martincevic and the company entered into a Transition Agreement pursuant to which Martincevic will serve as a consultant to the company from July 1, 2022 to December 31, 2022 and receive an amount equal to one-half of her current annual salary of $475,000 as compensation for providing those consultancy services.

09:33 EDT Knightscope announces contract for K5 Autonomous Security Robot - Knightscope announced that a US-based operator of casinos and gaming facilities with more than three dozen casino locations has signed its second contract for a K5 Autonomous Security Robo - the first was in Las Vegas, NV. The latest agreement is for the K5 to patrol the parking lots of an Iowa casino and hotel to deter criminal activity, as well as trespassers, and monitor the flow of people of interest, be they VIPs or known threats.

09:31 EDT Nordic American Tankers sells last 2002 built vessel - The company said, "We wish to inform you that we have sold the last of our originally four 2002 built suezmax tankers, the "Nordic Moon". The price is about $16 million net to NAT. The vessel will be delivered to the new owners during June 2022. We plan to take delivery of a newbuilding from Samsung Shipyard in South Korea at the end of June. It will start on a six year contract as from delivery. The first newbuilding from Samsung in this round was delivered to us in mid - May. The vessel started on a contract for 6 years when delivered from the yard. A strong balance sheet is essential. The NAT debt is low compared with other US listed tanker companies."

09:29 EDT Desert Peak Minerals, Falcon Minerals complete merger, creating Sitio Royalties - Desert Peak Minerals and Falcon Minerals Corporation (FLMN) announced the successful completion of their merger, creating Sitio Royalties (STR), a shareholder returns-driven company focused on large-scale consolidation of high-quality oil & gas mineral and royalty interests across diversified operators. Sitio will focus on maximizing value for all stakeholders and returning significant cash to shareholders. On June 3, 2022, prior to the consummation of the merger, Falcon effected a four-to-one reverse stock split of Falcon's Class A common stock and Class C common stock and formally rebranded as Sitio Royalties Corp. The Company's Class A common stock and warrants will initially continue trading on Nasdaq under the ticker symbols "STR" and "STRDW." In accordance with the terms of the merger agreement, Desert Peak became a subsidiary of Falcon's operating partnership. Chris Conoscenti, CEO of Sitio, said: "Sitio is guided by its commitments to best-in-class leadership and governance standards, capital discipline and a thoughtful approach to value-maximizing M&A. Sitio's distinguished profile as a leading consolidator in the minerals and royalties space will only continue to strengthen over time with the execution of our proven strategy, focusing on large-scale accretive acquisitions across diversified operators."

09:25 EDT Axis Capital announces changes to management - AXIS Capital Holdings announced a series of actions designed to "advance leadership in specialty underwriting - and the latest in a multi-year effort that has seen the Company increase profitability, lower volatility, and strengthen the portfolio, all with an eye toward delivering greater value to existing and new customers," the company said. The actions, which reflect the focus the company is placing on specialty underwriting, include: Appointing Vince Tizzio as CEO Specialty Insurance and Reinsurance; Expanding small-to-mid-sized enterprise solutions capability and associated suite of specialist products transacted digitally, Linda Ventresca named Head of Digital; Completing the shift of AXIS Re to a specialist reinsurer, with a commitment to Casualty, Specialty, A&H, and Credit lines, Ann Haugh named CEO of AXIS Re; Exiting its Property Reinsurance business, further reducing overall exposure to catastrophe risks; and Consolidating underwriting analytics and actuarial support functions under a global Chief Underwriting Officer.

09:19 EDT Snowflake launches new Cybersecurity workload - Snowflake, the Data Cloud company, announced the launch of a new Cybersecurity workload that enables cybersecurity teams to better protect their enterprises with the Data Cloud. Using Snowflake's platform and an extensive ecosystem of partners delivering security capabilities with connected applications, cybersecurity teams can quickly gain visibility and automation at cloud-scale. With Snowflake's Cybersecurity workload, customers gain access to the power and elasticity of Snowflake's platform to natively handle structured, semi-structured, and unstructured logs. Customers are able to efficiently store years of high-volume data, search with scalable on-demand compute resources, and gain insights using universal languages like SQL and Python, currently in private preview.

09:18 EDT Dolphin Entertainment's WCIP announces slate of NFT projects - Dolphin Entertainment announced that its Web3 marketing, consulting and communications agency, We Come In Peace, has developed a full slate of metaverse related clients and NFT projects, including ones with supermodel Bella Hadid and music industry mogul Troy Carter. In the first quarter of 2022, Dolphin Entertainment and WCIP partnered with celebrity chefs and restaurateurs Tom Colicchio and Spike Mendelsohn on Chfty, a collection of NFTs that provide owners with access to a culinary community led by the founders with virtual and in-person cooking events. The collection went on sale in March and sold out in less than 24 hours. WCIP's partnership with Chfty will continue in 2022 with the creation of a larger Web3 culinary ecosystem aimed at helping chefs, foodies, and brands integrate into Web3. WCIP was tapped by reBASE, the first ever geo-minting NFT platform, to help market and promote a new metaverse and NFT initiative co-founded by Bella Hadid. CY-B3LLA is a global community of humans, connected through a desire to create true, meaningful and compassionate relationships. Access to this community will be achieved through the acquisition of a limited collection of 11,111 unique NFTs, each featuring one-of-a-kind 3D scans of Hadid. The announcement of CY-B3LLA was unveiled first to her more than 52 million social media followers and then with key placements in publications such as Hypebeast, Glamour, NFT Now and many more. The NFT collection is expected to go on sale in mid June. In partnership with music and tech industry entrepreneurs Troy Carter and Suzy Ryoo, WCIP is also working on promoting a new NFT-gated community called the Venice Music Collective built for independent music artists. Membership via the NFT will serve as an access pass to an ecosystem for musicians including distribution, recording studios, creative workspaces, sync, analytics, financial services, equipment rental, community events and much more. In the coming months, WCIP will also help bring to market a generative NFT project that reimagines a new visual language for Web3 that is made up of variations of the 26 letters in the English alphabet called The Symbols. Developed by and in collaboration with some of the biggest names and influencers in Web3 and entertainment, owning a hand drawn Symbol NFT will unlock access to a global community, quarterly in real life events, exclusive merchandise, and proprietary decentralized applications that includes a word game. WCIP is also working on several projects with House of Attention, a creative and innovation studio specializing in immersive Web3 experiences, including Domonos, a collection of 100 hand-drawn pieces minted as NFTs and created by acclaimed Panamanian artist Miky Fabrega. Each Domonos NFT is a special piece of Latin American digital art history, with proceeds from each sale supporting Voces Vitales de Panama, a non-profit organization supporting underprivileged girls and women in Latin America and Surge, a female led organization focused on onboarding the next generation of women into Web3. This summer, WCIP will help launch The Dinner Roll Campaign, an art project that connects technology, charity and art in an effort to support the struggling restaurant and food service industries devastated by the global pandemic. More than 60 chefs and culinary elite, including; Danny Meyer, Rachael Ray, Eric Ripert, Amanda Freitag and Marcus Samuelsson have individually recreated Charlie Chaplin's iconic performance from the 1925 film "The Gold Rush." Each performance has been stitched together into a video mosaic art piece that will be auctioned off as an NFT with proceeds benefiting City Harvest, The James Beard Foundation, Rethink Food and World Central Kitchen. WCIP will continue to support Dolphin's strategic partnership with The Flower Girls, the fine art female-led NFT collection of 10,000 unique Flower Girls by revered artist Varvara Alay. Launched in December of 2021, The Flower Girls has surpassed over $15 million in sales to-date and is donating 20% of profits to a variety of children's charities voted on by the community. In addition, WCIP and Dolphin plans to bring its first wholly owned NFT project, Creature Chronicles, live this summer. Creature Chronicles is a multi-season graphic NFT event created by Anthony Francisco, who most recently served as a Senior Visual Development Artist at Marvel Studios, where he designed some of the world's most beloved characters and elements for the Marvel Cinematic Universe, from Baby Groot and Loki to the Dora Milaje of Black Panther and Ant Man + Wasp.

09:16 EDT Raytheon Technologies to move global headquarters to Arlington, Virginia - Raytheon Technologies announced that it will establish its global headquarters in Arlington, Virginia. The location increases agility in supporting U.S. government and commercial aerospace customers and serves to reinforce partnerships that will progress innovative technologies to advance the industry. Washington, D.C. serves as a convenient travel hub for the company's global customers and employees. The company will maintain its strong U.S. presence which includes 600 facilities across 44 states and territories. Each of the company's four business units currently have operations in Virginia. The new global headquarters office will be in Arlington's Rosslyn neighborhood alongside the Raytheon Intelligence and Space business. Raytheon Technologies has not accepted or sought any financial incentives from any state or municipality to support the establishment of the global headquarters office in Virginia.

09:15 EDT Matterport donates digital twin technology to SBP - Matterport announced that SBP, a U.S.-based non-profit organization focused on disaster resilience and recovery, has been selected as a partner organization for Matterport's Exploration to Equity social impact program. SBP, formerly known as the St Bernard Project, received a donation of Matterport products and services to create digital twins that will be used in its FEMA Appeals program to assist communities and help reduce the time between disaster and recovery for people that have been impacted by the devastating tornadoes that struck the Midwest in December 2021.

09:15 EDT AMD announces senior notes offering - AMD announced that it intends to offer, subject to market and other conditions, senior notes in an underwritten public offering. The Notes will be senior unsecured obligations of the Company. AMD intends to use the net proceeds from this offering for general corporate purposes. Barclays Capital Inc., BofA Securities, Inc., Credit Suisse Securities LLC, J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC are acting as joint book-running managers and underwriters for the Offering.

09:14 EDT Lightfoot, Franklin & White selects Oneplace Marketing & Business Development - Intapp announced that Lightfoot, Franklin & White, a trial and appellate firm serving the litigation needs of clients across the U.S., has selected OnePlace Marketing & Business Development as its new client relationship management suite.

09:13 EDT Crackle Plus enters CTV ad inventory agreement with Amagi - Amagi announced a Connected TV (CTV) ad inventory agreement with streaming platform and content owner Crackle Plus. Amagi's ADS PLUS is one of the largest first-party ad platforms in the CTV advertising landscape, supporting over 700 content brands on 2,000+ channels and delivering over 50 billion ad impressions. The massive supply of premium CTV inventory caters to the needs of both buyers and sellers through a unified CTV ad marketplace, backed by its proprietary advanced ad insertion technology and progressive ad technology. The deal between Amagi and Crackle Plus signals the industry interest in a new form of advertising agreement in the CTV marketplace: one that highlights the monetization opportunities for content owners and platforms in the CTV ecosystem as advertisers look to shift their ad budgets from traditional cable to fast-growing ad-supported streaming models.

09:12 EDT Payoneer Global, Fiserv collaborate to streamline cross-border payments - Payoneer (PAYO) and Fiserv (FISV) have teamed up to streamline how businesses deliver payouts to sellers, vendors, contractors, and consumers across borders. The collaboration allows businesses to access Payoneer's payouts platform via the Carat operating system from Fiserv, enabling the delivery of payouts all over the world, while reducing the accompanying costs. "Today's businesses realize that success and resilience against the unexpected both necessitate a diverse global network of customers and vendors," said Robert Clarkson, Chief Revenue Officer at Payoneer. "This has created exponential demand for easy and secure payment solutions to support cross-border transactions. We're proud to partner with Fiserv to fuel the growth of our mutual clients, and to move forward on our mission of giving businesses of all sizes the tools to be successful locally and globally."

09:10 EDT Gevo in new fuel sales pact with Japan Airlines for 5.3M gallons over 5 years - Gevo announces a new fuel sales agreement with Japan Airlines . The Agreement outlines the details for the purchase of 5.3M gallons per year of sustainable aviation fuel for five years with deliveries expected to begin in 2027.

09:09 EDT OneStream expands partnership with DISH Network - OneStream announces its expanded partnership with DISH Network to unify its corporate performance management solutions adding additional users to OneStream's Intelligent Finance platform. "OneStream proved to be an integral partner to not only replace our legacy systems, but to also streamline our financial processes with one unified platform," said Kyle Bemis, SVP of Finance, DISH Network. "OneStream's system provides the insights and data we need for agile decision-making while remaining flexible enough to grow with the company over time."

09:07 EDT Fortinet announces Public Sector Advisory Council - Fortinet announced its Fortinet Public Sector Advisory Council, The Fortinet Council includes highly esteemed global leaders, including: Gary Locke, Rachelle Chong, James R. Clapper, Peter Jennings, Sir Richard Shirreff, and Suzanne Spaulding. The members have excelled in a variety of government roles and missions and understand firsthand the value of public-private partnership and the critical importance of cybersecurity today. As part of the Council, members will contribute strategic counsel and leadership on some of the world's most critical cybersecurity challenges across the breadth of the public sector-both within the US and internationally, expanding Fortinet's commitment to securing public sector organizations worldwide.

09:07 EDT Forte Biosciences appoints Chen as CSO, President - Forte Biosciences (FBRX) announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer, CSO, and President. Prior to joining Forte, Dr. Chen was the Chief Medical Officer of Metacrine (MTCR), a clinical-stage company focused on the treatment of liver and gastrointestinal diseases.

09:06 EDT Crypto stocks slip as bitcoin falls back below $30,000 - Stocks levered to bitcoin prices are tracking lower in pre-market trading as the cryptocurrency fell back below the $30,000 level overnight, with the low around $29,200 seen as the lowest level in about a week. Bit Digital (BTBT) is down 3.1% at $1.57, Riot Blockchain (RIOT) is down 3.6% at $6.14, Marathon Digital (MARA) down 3.6% at $8.61, and Coinbase Global (COIN) down 4.8% at $67.30.

09:04 EDT Sumo Logic unveils Sumo Logic Threat Labs unit - Sumo Logic unveiled Sumo Logic Threat Labs, a threat research and security detection unit. The Threat Labs unit is among the expanded services and tools from Sumo Logic to help customers modernize security operations and achieve greater cyber-resilience. Sumo Logic will showcase the functionality of its security intelligence solutions from Booth #5463 at the RSA Conference 2022 this week in San Francisco. The Sumo Logic Threat Labs Unit is built to deliver a continuous stream of deep detection content, rapid response guidance, and actionable best practices to Sumo Logic security customers. The team is staffed with domain experts with backgrounds in forensics, incident response, and red/blue teaming, as well as offensive and defensive cyber operations in the United States military and intelligence services. Informed by deep human expertise, the Threat Labs Unit will also play a larger role in contributing advanced detection logic and best practices to the security community to help collectivize the defense.

09:03 EDT Medigus says ScoutCam completes verification, validation for camera solution - Medigus announced that ScoutCamm of which Medigus has a 27.02% percent ownership stake, has completed the verification and validation stage of ScoutCam's miniature camera solution with a Fortune 500 company. The announcement comes as ScoutCam prepares to commence mass production and enter the supply stage of its proprietary, patented equipment for delivery to the Fortune 500 customer. With this important V&V phase complete, ScoutCam believes sales revenue could reach tens of millions of dollars as ongoing supply agreements with the customer accumulate in the coming years.

09:02 EDT Digimarc partners with Sealed Air - Digimarc (DMRC) announced the company has partnered with Sealed Air (SEE), to bring product digitization to markets like food proteins, eCommerce fulfillment, industrials, and consumer goods at scale through smart packaging. Product digitization allows brands to maximize the value of every package to deliver on consumer demands for authenticity, sustainability, and personalized consumer experiences. Product digitization also drives operational improvements by illuminating a product's supply chain journey.

08:57 EDT Lightwave Logic calls Kerrisdale Capital report 'false and misleading' - "Lightwave Logic provided a response to a report issued by short selling firm Kerrisdale Capital about Lightwave Logic that the company believes contains statements that are false and misleading. By its own admission, Kerrisdale Capital does not stand by the accuracy, timeliness, or completeness of its misleading report. At the time of the misleading report's publication, Kerrisdale Capital declared that it held short positions and put options on Lightwave Logic's common stock. The misleading report is not an independent and disinterested report, its primary purpose is to devalue the company's stock price in order for the short selling firm to profit at the expense of Lightwave Logic's shareholders. Lightwave Logic stands by all past statements contained in its press releases, investor presentations and filings with the U.S. Securities and Exchange Commission as it continues on its path to revenue. Lightwave Logic continues to expand its activities and operations with the objective of commercializing its electro-optic polymer technology, and it continues to focus on creating value for its shareholders."

08:52 EDT Itron released its 2021 Environmental Social Governance report - Itron released its 2021 Environmental Social Governance, ESG, Report, highlighting its commitment to long-term sustainability through advanced initiatives which increase efficiency and reduce carbon emissions. Through its advanced technology solutions and partnership with utilities, Itron is enhancing efficient management of energy and water as well as educating consumers on how to take an active role in managing resource use. As part of Itron's ESG strategy, the company has set aggressive objectives and enterprise initiatives that align efforts with the United Nation Sustainable Development Goals including: Fifty percent reduction in Scope 1 and Scope 2 greenhouse gas emissions by 2028; Carbon-neutral operations by 2035; Net zero by 2050 or sooner; Pledge to assist and enhance consumers and utilities to improve their sustainability through advanced solutions and services. "We are facing a critical time in history where today's decisions on how we conserve and manage our energy and water resources will shape the lives of future generations," said Tom Deitrich, Itron's president and CEO. "Itron continues to build sustainability and ESG initiatives into every aspect of our operations and push the industry to do so as well by offering innovative solutions for utilities and their customers and working with our employees to unlock their resourcefulness. Our efforts are aligned with the U.N. Sustainable Development Goals, and as a participant of the U.N. Global Compact, we adhere to its principles-based approach to responsible business practice and further Itron's vision to create a more resourceful world."

08:51 EDT Aramark, Starr announce plans for new restaurant at Wells Fargo Center - Wells Fargo Center, Aramark Sports + Entertainment, and Starr Restaurants announced plans for a new sit-down restaurant concept at Wells Fargo Center. This will mark Aramark and Starr Restaurants' first full-scale restaurant project as part of the strategic collaboration announced by the two Philadelphia-based organizations in 2021. The restaurant will replace The Grille at Wells Fargo Center in South Philadelphia and is expected to open in October at the start of the 2022-23 NHL and NBA seasons. "As we work closely with Starr Restaurants and Wells Fargo Center to develop this new concept, Aramark is focused on the ways in which we can showcase our culinary agility and customize the game-day experience to meet the needs of our client and the expectations of fans," said Alison Birdwell, President and CEO of Aramark Sports + Entertainment. "This is an exciting collaboration between three industry leaders, and we can't wait to deliver a brand-new experience that leverages the creativity and expertise of all parties involved."

08:49 EDT Duos Technologies Group joins Nvidia Metropolis partner program - Duos Technologies Group announced it has joined the NVIDIA Metropolis partner program. Metropolis is an application framework and set of developer tools that bring to market a new generation of vision artificial intelligence applications to make the world's most important spaces and operations safer and more efficient.

08:48 EDT SeaStar Medical and SPAC LMF Acquisition publish SCD 005 clinical study data - SeaStar Medical and LMF Acquisition Opportunities , a special purpose acquisition company, announced the publication of results from SeaStar Medical's pilot SCD 005 clinical study to evaluate the safety and clinical outcomes of extracorporeal immunomodulation treatment with SeaStar Medical's Selective Cytopheretic Device in COVID-19 patients with multiple organ failure in the intensive care unit . The article, "Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients," was published in the May 2022 issue of the Society of Critical Care Medicine's Critical Care Explorations. "The study met its primary endpoints, and the results published in Critical Care Explorations are an important step in validating the role neutrophils and monocytes play as the effector cells responsible for a dysregulated systemic inflammatory response. By removing the most activated neutrophils and monocytes from circulation, the SCD's immunomodulatory impact enables a return to a regulated healing process," said Dr. H. David Humes, professor of nephrology at University of Michigan, one of the lead investigators of the study and a director of SeaStar Medical.

08:46 EDT ChampionX closes debt refinancing - ChampionX Corporation announced that it has refinanced its existing credit facilities with a restated senior secured credit facility, amending and restating its 2018 senior secured credit facility. The restated agreement provides a $625 million 7-year term loan B and a $700 million 5-year revolving credit facility. The Company will use the proceeds from the term loan, and an initial draw from the revolving credit facility, to repay outstanding amounts under its 2018 senior secured credit facility and repay and terminate its 2020 term loan facility, and to redeem all outstanding 6.375% Senior Notes due 2026. Proceeds from future draws of the revolving credit facility will be used for working capital and other general corporate purposes.

08:44 EDT BiondVax receives 'supportive' advice from PEI for Covid-19 NanoAb plans - BiondVax Pharmaceuticals announced receipt of supportive minutes of its recent Scientific Advice meeting with the Paul Ehrlich Institute in Germany. The Scientific Advice addressed preclinical, clinical, and manufacturing development plans for the COVID-19 NanoAb therapy that BiondVax is developing based on an exclusive license from Max-Planck-Innovation GmbH and an accompanying research collaboration with the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Gottingen. The Scientific Advice Meeting minutes sent by PEI state, "Generally, the PEI concurs with the proposed proof-of-concept study...and the overall nonclinical strategy that are required to support further clinical development as well as potential regulatory approval." Notably, PEI indicated support for conducting a combined Phase 1/2a first-in-human clinical trial that would include patients with confirmed COVID-19 infection. This would allow BiondVax to assess safety and efficacy in a single trial rather than the typical two trials, and therefore significantly accelerate its development timeline. This combined Phase 1/2a trial would follow preclinical proof-of-concept and toxicology, with a target start date in 2023.

08:43 EDT Quantum Computing unveils QAmplify suite of quantum software technologies - Quantum Computing unveiled QAmplify, a suite of quantum software technologies that expands the processing power of any current quantum computer by as much as 20x. QAmplify is capable of supercharging any quantum computer to solve real-world realistic business problems today. The Company is actively working with customers and partners in scaling the amplification capabilities of its ready-to-run Qatalyst software, which is designed to eliminate the need for complex quantum programming and runs seamlessly across a variety of quantum computers. QCI has filed for patents on QAmplify technology.

08:42 EDT II-VI completes tape-out of Steelerton DSP for 100 Gbps coherent transmission - II-VI Incorporated announced that it completed the tape-out of its Steelerton digital signal processor for 100 Gbps coherent transmission in optical access and aggregation networks. The growth of 5G wireless and high-speed broadband services is driving the explosive demand for coherent transceiver technology optimized for optical access networks. While service providers currently deploy coherent transceivers in core networks and datacenter interconnects, they are seeking new designs that meet their high volume, low cost, low power dissipation, and small size requirements for access networks. II-VI's Steelerton DSP, miniaturized and with ultralow power dissipation, typically of 2 W, was designed specifically to enable 100 Gbps digital coherent optics (DCO) in a pluggable QSFP28 format, one of the most widely deployed 100 Gbps transceiver form factors in access networks.

08:40 EDT 1PointFive, Carbon Engineering announce direct air capture deployment approach - 1PointFive, a subsidiary of Occidental's Low Carbon Ventures business, and Carbon Engineering, announced a Direct Air Capture plant deployment approach to help execute large numbers of DAC projects around the world. The deployment approach standardizes the design of plants to help deliver complete, operationally ready DAC facilities to local partners. Through this process, plant components and equipment will be modularized, mass manufactured and then assembled on-site using an established supply chain of vendors. This approach combines the partners' DAC technology, large-scale carbon dioxide management, project experience and extensive storage infrastructure. CE will provide the DAC technology, while 1PointFive will build and deploy the DAC plants, leveraging Oxy's strong project engineering and delivery expertise. Local partners will complete the team, bringing complementary experience and regional expertise. From CE's dedicated DAC development and innovation centre in British Columbia, Canada, CE and 1PointFive are continuing to optimize DAC technology in real-world operations and reduce the cost of capture per tonne. The deployment approach also enables the swift introduction of next generation improvements into commercial facilities. 1PointFive has announced a scenario of deploying 70 DAC facilities by 2035, each with an expected capacity of up to 1 million tonnes per year, under current policy and voluntary and compliance market scenarios. The company estimates that up to 135 DAC facilities could be deployed with an increase in global policy initiatives and demand in the voluntary market. 1PointFive's first DAC facility is progressing through front-end engineering and design and is expected to be operational in late 2024 in Texas. Advance product sales for this facility, including agreements with Airbus, Shopify and ThermoFisher, and offtake frameworks, like the agreement with SK Trading International, signal the increasing demand from the voluntary market for large-scale, DAC-enabled climate solutions.

08:38 EDT Minim announces WiFi 6 Modem/Router placement in Best Buy locations - Minim announces a retail shelf expansion with its first WiFi 6 Modem/Router product placement in hundreds of Best Buy locations across the United States. The Motorola MT8733 DOCSIS 3.1 Cable Modem comes with a powerful, built-in 4x4 AX6000 router; the motosync app, powered by Minim; and two phone lines for Xfinity Voice support. For the first time, Best Buy shoppers with Gigabit speed broadband plans and Xfinity Voice have the option to purchase their own modem/router and save on rental fees while improving their home network security and performance.

08:38 EDT Rush Street adds online sportsbook to existing online casino in West Virginia - Rush Street Interactive announced it is adding its online sportsbook to its existing online casino at BetRivers in West Virginia. Now sports fans across the Mountain State, aged 21 and over, can join gaming enthusiasts to place bets quickly and securely from the integrated BetRivers iOS and Android apps and website. "We expect our BetRivers sportsbook app to be well received as many West Virginians are now familiar with the BetRivers brand and have come to appreciate and trust our high-quality products and responsive customer service," said Richard Schwartz, Chief Executive Officer of RSI. "We are pleased that our integrated app will provide one convenient location for players in West Virginia to switch effortlessly between the casino and sportsbook using phones, tablets and computers to experience all that we have to offer, from spreads, moneylines, parlays, single game parlays, and player props to slots, tables games, and live dealer experiences."

08:37 EDT AlloVir reports preliminary Phase 2 data of VST therapy for treating BKV - AlloVir announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell, VST, therapy, for the treatment of BK viremia, BKV, in adult kidney transplant recipients. These data were shared in an oral plenary presentation at the American Transplant Congress, ATC, in Boston. This ongoing, randomized, double-blind, placebo-controlled Phase 2 study is evaluating the safety and tolerability of posoleucel for the treatment of BK viremia in 61 adult kidney transplant recipients with BK viremia between 350-10,000,000 copies/mL. Enrollment in the study has completed. At the time of the data cut-off for this preliminary blinded analysis, 61 patients had received at least one dose of posoleucel or placebo at a median of 458 days post-transplant. The primary study endpoint is safety and tolerability of posoleucel versus placebo. In this preliminary blinded analysis, headache, which was reported in six patients was the only adverse event judged by investigators to be related to study drug that occurred in more than 5% of patients. No grade 3-4 adverse events, treatment-related serious adverse events, treatment discontinuations due to adverse events, or deaths were reported. There were no cases of graft rejection and no episodes of graft versus host disease or cytokine release syndrome. One patient developed de novo donor-specific antibodies; these antibodies were not found to be directed against posoleucel antigens in the matching cell line. The key secondary endpoint of the study is change in BK viremia in patients receiving posoleucel versus those receiving placebo. Declines in median BK viral load were observed in this blinded dataset irrespective of the baseline BK viral load. At baseline, 34 patients had a viral load below 10,000 copies/mL. The median viral load in these 34 patients was 2,042 copies/mL on Day 1. Among the 14 patients who had reached the Week 12 timepoint at the time of this analysis, the median viral load had declined to 245 copies/mL. At baseline, 27 patients had a viral load above 10,000 copies/mL and the median viral load was 190,546 copies/mL at Day 1.

08:36 EDT Clearmind announces pre-clinical results for cocaine addiction treatment - Clearmind Medicine announced pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University was designed to evaluate possible reward-like effects of MEAI, on male Sprague-Dawley rats based on the Conditioned Place Preference model. Rats previously conditioned with cocaine received either cocaine or MEAI at doses of 2.5, 5, 10 and 20 mg/kg. Rats treated with MEAI spent less time in the compartment associated with cocaine. Results suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving, and that the compound was not itself addictive. The 5 mg/kg dose was found the most effective dose and selected for further study. The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction.

08:34 EDT Rush Street adds its online sportsbook to its existing online casino - Rush Street Interactive announced it is adding its online sportsbook to its existing online casino at BetRivers in West Virginia. Now sports fans across the Mountain State, aged 21 and over, can join gaming enthusiasts to place bets quickly and securely from the integrated BetRivers iOS and Android apps and website. "We expect our BetRivers sportsbook app to be well received as many West Virginians are now familiar with the BetRivers brand and have come to appreciate and trust our high-quality products and responsive customer service," said Richard Schwartz, Chief Executive Officer of RSI. "We are pleased that our integrated app will provide one convenient location for players in West Virginia to switch effortlessly between the casino and sportsbook using phones, tablets and computers to experience all that we have to offer, from spreads, moneylines, parlays, single game parlays, and player props to slots, tables games, and live dealer experiences."

08:33 EDT Zoetis announces agreement to acquire Basepaws - Zoetis announced an agreement to acquire Basepaws, a private company which provides pet owners with genetic tests, analytics and early health risk assessments. The acquisition will advance Zoetis' portfolio in the precision animal health space and will inform and shape its future pipeline of petcare innovations. Financial terms of the agreement are not being disclosed. "The Basepaws team has done an amazing job demonstrating how genetic testing and data can improve how we care for the pets in our lives," said Abhay Nayak, Executive Vice President of Strategy, Accelerated Growth Businesses and Commercial Development. "With the addition of Basepaws, Zoetis will continue to strengthen our portfolio of products for precision animal health, across genetics, diagnostics and data analytics for pets and livestock. We are also excited by how Basepaws' feline genomic and microbiome database will help enhance our R&D capabilities and inform the future of our petcare pipeline."

08:32 EDT JanOne announces patent covering method to improve nerve function with JAN101 - JanOne announced that a patent was issued that covers a method of improving nerve function using JAN101. JAN101, formerly known as TV1001SR, is a potential treatment for peripheral artery disease, or PAD, a vascular disease that affects more than 8.5 million people in the U.S. and more than 60 million people worldwide. "This patent further protects JanOne Inc.'s product for use in treating PAD by extending the use of JAN101 to treat the nerve damage caused by microvascular disease," said Tony Giordano, JanOne's Chief Scientific Officer. "Microvascular disease is a major problem for PAD patients: it leads to restricted blood flow in the affected limb, which in turn leads to nerve damage and severe pain. Recent studies have in fact suggested that PAD is a microvascular disease, so the observation that JAN101 improves microvascular and nerve function is crucial in treating this disease."

08:31 EDT Tupperware Brands to sell Nutrimetics beauty business, terms not disclosed - Tupperware Brands announces that it has entered into a definitive agreement for the sale of its Nutrimetics beauty business, which operates in Australia, New Zealand, and France. This transaction advances the company's turnaround plan strategy of divesting non-core assets. Terms of the transaction, including the anticipated closing date, have not been disclosed. The sale of the Nutrimetics beauty business follows the company's sale of its Avroy Shlain beauty business in South Africa during the first quarter of 2021, and the sale of its House of Fuller beauty business in Mexico during the second quarter of 2022.

08:30 EDT Jones Soda, Simply Better Brands terminate LOI - Simply Better Brands and Jones Soda Co. announce that, due to current market conditions, SBBC and Jones have terminated the previously announced letter of intent. "We are disappointed that due to current market conditions we are unable to move forward with our intended transaction at this time. The Jones Soda brand is one we felt confident would add tremendous value to our existing platform and ultimately be accretive to shareholder value. We wish Jones management and their board much success in their future," says Kathy Casey, CEO of Simply Better Brands. "Due to the decline in current market conditions, we regrettably are unable to continue with the proposed transaction with SBBC. We are certain that Simple Better Brands and Jones will continue to find successful business opportunities in the future, despite this shift in direction for both companies," says Mark Murray, CEO of Jones Soda.

08:29 EDT Evaxion Biotech secures equity financing up to $40M from Lincoln Park - Evaxion Biotech announced that it has entered into a committed equity purchase agreement with Lincoln Park Capital Fund, for the issuance and sale, from time to time, of up to $40 million of its American Depositary Shares, each of which represents one ordinary share, DKK 1 nominal value, of the Company. Under the terms of the Agreement, Evaxion has the right, at its sole discretion, but not the obligation, to sell to LPC up to $40 million of its ADSs over the 36-month term of the Agreement, subject to certain conditions. Evaxion had cash and cash equivalents of $31.4 million at the end of the first quarter of 2022 and expects its cash position, without proceeds from the Agreement, to be sufficient to fund operating expenses and capital expenditure requirements through at least the next 12 months.

08:28 EDT Otonomo appoints Meir Moshe to its board of directors - Otonomo Technologies (OTMO) welcomes Meir Moshe to its Board of Directors. Moshe will work alongside fellow board members to further Otonomo's mission to deliver a new generation of mobility experiences and services. A seasoned technology veteran whose career spans over four decades, Moshe is known for his expertise in finance. At Radware (RDWR), he served as the CFO for 17 years. He also has extensive experience as a director and member of the audit committee for numerous public companies, including Ability Inc., Carasso Motors and Albert Technologies Ltd.

08:26 EDT Greywood intends to include Shinggo Lu on Enthusiast Gaming board - Greywood Investments, LLC, which, together with its associates and affiliates is the largest shareholder of Enthusiast Gaming Holdings, announced that it intends to include Shinggo Lu, Co-Founder and General Manager of U.GG, as a member of the new Board that would replace the Company's incumbent directors. U.GG was acquired by Enthusiast in November 2021. On June 3, 2022, Enthusiast announced it had awarded the vendors of Outplayed Inc., the company that owned U.GG prior to its sale to Enthusiast, 11.5 million shares to satisfy certain deferred earn-out payments, in advance. U.GG's founders and employees now collectively own approximately 6.75 million shares, or 4.5% of the issued and outstanding shares of Enthusiast. Greywood has previously nominated Jon Dakss, Raphael Danon, David Goldhill, Mark Klein, Janny Lee, and Dan Petrozzo to stand for election on Enthusiast's Board. Details on all seven people, and other information about the Upgrade Enthusiast campaign, can be found at www.UpgradeEGLX.com. Since announcing its annual meeting and record date, the Company has twice rescheduled both without providing any explanation. Shareholders will finally have the opportunity help the Company realize its full potential by voting for the new slate at the meeting on July 19, 2022.

08:25 EDT Virgin Orbit announces joint mission between UK, US - Virgin Orbit announces that a joint mission between the United Kingdom's, UK, Defense Science and Technology Laboratory and the United States, US, Naval Research Laboratory, NRL, is expected to be lofted on the first space launch out of Spaceport Cornwall later this year. The government agencies' joint Coordinated Ionospheric Reconstruction CubeSat Experiment, CIRCE, is supported by the U.S. Department of Defense's Space Test Program, STP, which is organized under the U.S. Space Force's Space Systems Command, SSC. CIRCE will utilize two 6U CubeSats flying in tandem formation to measure the ionosphere and radiation environment from multiple vantage points. The mission will support the two countries' joint development of a wide range of civil and defense applications, including GPS, radar, communication systems, and sensing technology. "We are honored to host this joint mission between the U.S. and U.K. Governments on the launch from Cornwall," said Virgin Orbit CEO Dan Hart. "This demonstration, chosen to fly on the United Kingdom's first space launch from its territory, exhibits the powerful value of collaboration between our two countries and their mutual commitment to delivering the full value of space access for all."

08:21 EDT Union Pacific falls 4% to $216.11 after the company's updated view on margins - Peers Canadian Pacific (CP) is down 1.9%, CSX Corp (CSX) is down 1.9%, and Norfolk Southern (NSC) is down 2.1%.

08:21 EDT Alpine Immune Sciences appoints Sandler as CMO - Alpine Immune Sciences (ALPN) announced the appointment of industry veteran Andrew Sandler, M.D., as its Chief Medical Officer, CMO. Dr. Sandler joins Alpine from Kiadis Pharma, a Sanofi Company, where he was Chief Medical Officer. Dr. Sandler's anticipated start date is August 17, 2022. Dr. Sandler brings over 25 years of industry and clinical practice experience. Prior to his role at Kiadis Pharma/Sanofi, Dr. Sandler was Senior Vice President of Medical Affairs at Medivation (PFE).

08:19 EDT RumbleON announces 10-year exclusive agreement with City of Sturgis - RumbleOn announced that it has entered into an exclusive Sponsorship Agreement with the City of Sturgis, South Dakota for its annual City of Sturgis Motorcycle Rally event. This Sponsorship Agreement between RumbleOn and the City of Sturgis consists of a 10-year exclusive Powersports category sponsorship for the City of Sturgis Motorcycle Rally events and a prime downtown retail property lease through 2031. Peter Levy, RumbleOn President and COO stated, "There is no greater event in the motorcycle community for displaying the passion of ownership than the iconic City of Sturgis Motorcycle Rally. We are thrilled to memorialize our continued partnership with the City of Sturgis as their exclusive Powersports category sponsor." Levy continued, "Seldom do brands have the opportunity to promote their products on the biggest stage to the highest concentration of their most defined demographic. Every one of the hundreds of thousands of annual attendees sits on the seat of the motorcycles we proudly sell."

08:19 EDT TransUnion to make Epsilon data available via the TruAudience Data Marketplace - TransUnion announced a partnership to make data from Epsilon, an advertising and marketing technology company, available via the TruAudience Data Marketplace. The relationship marks one of the largest audience targeting partnerships across Connected TV, smart speakers and gaming consoles. Brands and agencies can now access audience insights from Epsilon's top-ranked consumer database of 250 million U.S. consumers mapped across TransUnion's household identity graph covering more than 80M U.S. connected homes. Through this partnership, brands and agencies can create custom audiences based on thousands of attributes, thereby allowing them to reach each person with personalized messages across channels.

08:19 EDT Union Pacific says fuel prices to pressure margins below original forecast - In a regulatory filing, the company states: "On June 7, 2022, CFO Jennifer L. Hamann and Kenny G. Rocker, Executive Vice President - Marketing and Sales of Union Pacific Railroad, the principal operating subsidiary of the company, addressed the 2022 UBS Global Industrials and Transportation Conference. Ms. Hamann reaffirmed that the company expects to achieve full year fiscal 2022 operating ratio improvement as compared to full year fiscal 2021 results. However, she provided that the increased pressure from fuel prices and other cost inflation as well as higher network costs will pressure incremental margins below the original forecast of mid-60 percent. The Company now expects all-in inflation, excluding locomotive fuel, for the full year to be around 4%. Ms. Hamann also presented that these same pressures make achievement of the company's full year operating ratio starting with a '55' unlikely."

08:17 EDT Amneal Pharmaceuticals releases 2021 Corporate Responsibility Report - Amneal Pharmaceuticals announced the release of its second annual Corporate Responsibility Report. The report showcases the Company's continued progress in deepening its commitment to environmental, social, and governance integration across Amneal strategy, culture and operations. Updates on actions the Company has taken in key ESG areas are highlighted alongside the social impacts of our business as well as the latest information on our diversity data, employee development and well-being offerings, environmental programs and responsibility plans for 2022. "2021 was a year of continued evolution at Amneal. Our employees delivered a year of strong execution, including a robust cadence of new product innovations, enhanced operating efficiencies, and strategic M&A bolstering our core capabilities, pipeline, and portfolio. At the same time, we made meaningful progress in elevating our commitment to ESG and more deeply integrating responsibility within our business strategy, culture and operations," said Chirag and Chintu Patel, Co-Chief Executive Officers.

08:17 EDT Lockheed Martin selects MDA for SDA's Tranche 1 Transport Layer program - MDA Ltd. announced it has been awarded a contract from Lockheed Martin as part of the Space Development Agency Tranche 1 Transport Layer program. MDA will design and build antennas and antenna control electronics for the 42 low Earth orbit satellites to be produced by Lockheed Martin as part of SDA's T1TL constellation. This includes steerable Ka-Band and Link-16 antennas, as well as the satellites' GPS antennas.

08:16 EDT Olink, Singular Genomics collaborate for Olink Explore on G4 Max Read kits - Olink Holding announced a collaboration to enable use of the Olink Explore high-throughput proteomics platform with the Max Read kits on the Singular Genomics G4 Sequencing Platform. Singular Genomics and Olink are pursuing an integrated end-to-end solution pairing the existing Olink Explore assay and the newly announced Max Read kits on the G4. The Max Read kit will offer up to four billion reads per run across four flow cells and 16 independent lanes. The new kit is expected to be a strong solution for the Olink Explore assay that will translate into significant flexibility, cost, and throughput benefits. This non-exclusive collaborative framework is a continuation of Olink's strategy it has executed in NGS since 2020 and combines the strengths of both companies' technologies. These efforts are intended to provide Olink customers with options in choosing the sequencing platform that is optimal for their needs and to expand the portfolio of applications for G4 customers.

08:14 EDT Cybin aquires DMT clinical study from Entheon Biomedical - Cybin announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine, DMT, study from Entheon Biomedical to accelerate the clinical development path for CYB004, Cybin's proprietary deuterated DMT molecule for the potential treatment of anxiety disorders. The Phase 1 EBRX-101 study, now named CYB004-E, is being conducted in the Netherlands at the Centre for Human Drug Research, a leading independent foundation specializing in innovative early-stage clinical drug research, in 50 healthy volunteers who smoke tobacco - making it the largest Phase 1 DMT clinical study conducted to date. Pending the close of the Acquisition, the CYB004-E study is expected to yield essential safety and dosing optimization data and will replace Cybin's planned pilot study for CYB004 that was expected to commence in the third quarter of 2022. Entheon will continue to support the CYB004-E study and act as external consultants to Cybin. "The most precious commodity in drug development is time and acquiring this robust Phase 1 study already underway potentially accelerates the CYB004 development program by approximately nine months. The PK findings from the CYB004-E study should also help to inform the clinical path forward for this innovative and proprietary molecule," said Doug Drysdale, Chief Executive Officer of Cybin. "This transaction also provides Cybin with access to a world-class research foundation and the privilege to work with the Entheon team, who offer a wealth of knowledge and expertise in this psychedelic class."

08:13 EDT United Natural Foods jumps 7% to $48 after Q3 results beat, FY22 guidance raised

08:12 EDT Booz Allen awarded NASA CyPrESS contract - Booz Allen Hamilton announced it was awarded the National Aeronautics and Space Administration, NASA, Cybersecurity and Privacy Enterprise Solutions and Services, CyPrESS, contract-a hybrid indefinite-delivery/indefinite-quantity, IDIQ, single award contract with a total potential value of $622.5M-to provide a complete range of cybersecurity and privacy enterprise solutions and services for NASA's Office of the Chief Information Officer, OCIO. For the first time, this contract brings together all aspects of cybersecurity across the NASA enterprise under one contract to include IT systems, operational technology systems, and mission systems. Work will support all NASA centers and facilities from May 31, 2022 through September 30, 2023, with four option periods running through September 2030. "We're honored that NASA has awarded Booz Allen with the groundbreaking CyPrESS IDIQ contract, which seeks-for the first time-to centralize NASA's cybersecurity posture under one strategic line of work," said Andrea Inserra, executive vice president at Booz Allen Hamilton. "We recognize that NASA's current cyber needs must advance and evolve to protect its more complex missions of the future, and we look forward to building on our long-standing partnership to support NASA's important research, missions, and operations-paving the way to send humans beyond the Moon to Mars-while protecting its people, assets, and information from threats."

08:11 EDT Poet Technologies appoints Theresa Lan Ende as board advisor - POET Technologies announced that it has appointed Theresa Lan Ende, currently Chief Procurement Director of Arista Networks, as an advisor to the Company's Board of Directors. The Company also announced that it intends to nominate Theresa Lan Ende as a director at its Annual General Meeting currently scheduled for October 6, 2022.

08:10 EDT Qorvo announces QPA1724 amplifier - Qorvo announced a 20W GaN-on-SiC power amplifier for defense and commercial satellite applications, including low earth orbit constellations. Qorvo's QPA1724 amplifier operates at 17.3 to 21.2 GHz and offers twice the power of competing PAs, along with excellent wideband linear power, gain and power added efficiency in a compact surface mount package. The market-leading QPA1724 is optimized for wide bandwidth multi-carrier high data throughput satellite applications.

08:09 EDT Cracker Barrel CEO cites 'high inflationary pressures' in Q3 - Commenting on the third quarter results Cracker Barrel President and CEO Sandra Cochran said, "A challenging macro environment, including deteriorating consumer sentiment and high inflationary pressures, impacted both our top and bottom lines in the third quarter. Despite these challenges, our teams worked hard to deliver on our mission of Pleasing People and continue our strong retail and off-premise performance. Going forward, we are pursuing a variety of strategic initiatives to grow the business, including focusing on store-level execution to provide a superior guest experience, expanding Maple Street Biscuit Company, and positioning Cracker Barrel to be even more attractive to both our core guests as well as a broader audience. Despite the challenges of the present environment, we are optimistic that these initiatives will position us well for future growth, and I'm confident that our teams will deliver them for the benefit of our guests and our shareholders."

08:08 EDT Observed safety profile supports bilateral dosing of ProKidney's REACT -007 - ProKidney announced an update on its REGEN-007 Phase 2 clinical study of REACT. Background - ProKidney's REGEN-002 trial is a multi-center, randomized Phase 2 trial that enrolled 81 stage 3/4 CKD diabetic patients who received two injections in the same kidney six months apart. Patients are being followed for up to two years. Previously disclosed preliminary and interim data as of September 2021 showed promising results with a majority of patients achieving disease stabilization or improved kidney function. Based on an observed favorable safety profile in REGEN-002 and other previous studies, and a signal of improved kidney function, in REGEN-007 ProKidney is proceeding with the injection of REACT into both kidneys. ProKidney expects that injecting both kidneys will result in increased therapeutic effect as compared to injecting a single kidney, as the systemic effects of Type-2 diabetes mellitus impact both kidneys. By injecting both kidneys, patients have maximal exposure to REACT cells, with the potential to impact a greater proportion of damaged renal tissue. .. "This study is expected to provide valuable insights into the potential benefits of treatment with doses of REACT in each kidney, and together with the ongoing Phase 3 program, is expected to support our planned biologics license application submission to the FDA in 2025," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "We believe that dosing both kidneys with REACT can enhance our mission of sustaining renal function by augmenting the repair process over the course of a patient's life. We look forward to testing this hypothesis as we continue to recruit subjects, and to reporting data from our enhanced delivery approach in 1Q23."ProKidney, a pioneer in the treatment of CKD through innovation in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, REACT is a first-of-its-kind, patented, disease-modifying, autologous cellular therapy with the potential not only to slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT has received Regenerative Medicine Advanced Therapy designation, as well as FDA and EMA guidance, supporting the Phase 3 clinical program that launched on schedule in January 2022. On January 18 ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings .

08:07 EDT FIS delivers derivatives solution to Societe Generale - FIS (FIS) announced that Societe Generale (SCGLY) has signed an extended agreement, selecting the financial technology leader for the strategic transformation of its derivatives clearing and settlement technology. As part of the agreement, the investment bank and financial services group will transition their existing derivatives clearing and settlement IT environment to FIS Cleared Derivatives Suite. "The listed derivatives clearing business is a core part of our Prime Services business franchise at Societe Generale. We are recognized by our customers, and the industry, as a market leader in this space. Our decision to select FIS to provide our next generation post-trade clearing technology, represents a significant investment, with a trusted partner, to support the long term growth of this business," said Christophe Lattuada, Chief Operating Officer of Global Banking & Investor Solutions at Societe Generale.

08:06 EDT L&F Acquisition Corp. transfers listing to NYSE American - L&F Acquisition announced that it will transfer its listing to the NYSE American, where it has been approved to list. In connection with the transfer, LNFA will voluntarily delist from The New York Stock Exchange. LNFA's decision to transfer to the NYSE American was motivated by several factors, including more favorable thresholds for continued listing on the NYSE American. Following the transfer, LNFA will continue to file the same types of periodic reports and other information it currently files with the Securities and Exchange Commission. LNFA anticipates the transfer to the NYSE American to occur on or about June 10, 2022.

08:05 EDT Oracle completes acquisition of Cerner - Oracle (ORCL) announced that a majority of the outstanding shares of Cerner (CERN) were validly tendered, and the other conditions to the tender offer have been satisfied or waived. The deal will close on June 8. American Stock Transfer & Trust Company, the depositary for the tender offer, has indicated that as of 12:00 midnight, Eastern time, at the end of the day on June 6 approximately 204,280,589 Shares, or 69.2% of the total Shares, have been validly tendered.

08:03 EDT scPharmaceuticals announces abstracts accepted for AAHFN meeting - scPharmaceuticals announced that the Company has had two abstracts accepted for presentation at the American Association of Heart Failure Nurses 18th Annual Meeting, which is being held June 15-18 in Orlando, Florida. "We are very pleased to present the primary results from the FREEDOM-HF study as an encore oral presentation at this year's AAHFN annual meeting. As first reported in July 2021, heart failure patients presenting to the emergency department with worsening congestion and managed as outpatients with our investigational product, FUROSCIX incurred nearly $18,000 less in 30-day heart failure-related costs than a matched comparator group identified from a claims database that was treated in the inpatient hospital setting with intravenous furosemide for a median of two days," stated John Tucker, chief executive officer of scPharmaceuticals. "In addition, key secondary endpoints from the FREEDOM-HF study that demonstrated that patients who received FUROSCIX had marked improvements in quality of life, satisfaction with the intervention and clinically meaningful reductions in natriuretic peptides will be presented in a moderated poster session. With our FUROSCIX New Drug Application accepted and a Prescription Date User Fee Act action date set for October 8th of this year, we believe we now have a line of sight to potentially introducing a new and much-needed treatment option along the heart failure care continuum. To that end, we continue to prepare for a successful Q4 2022 commercial launch should FUROSCIX be approved," Mr. Tucker concluded.

08:02 EDT Schneider Electric, Claroty collaborate to enhance industrial cybersecurity - Schneider Electric has announced its collaboration with Claroty, the security company for cyber-physical systems across industrial, healthcare, and commercial environments. The agreement builds on the existing relationship between the two leading companies and leadership in their respective industries. Schneider Electric will now integrate The Claroty Platform into their offering, enabling them to better address new cybersecurity concerns, including protection, safety and insurance for industrial customers. "We see cybersecurity as a key differentiator," said Jay Abdallah, VP Cybersecurity Services, Schneider Electric. "Through our collaboration with Claroty, we are reinforcing its importance to the industrial process and taking active steps to mitigate new challenges. We are entering a new era of openness in the industrial world and the same is true for cybersecurity. We are pleased to partner with Claroty and continue our work together to create the most secure assets in the market."

07:58 EDT ASGN secure multiple award IDIQ contract supporting FCC application development - ECS, a subsidary of ASGN, has secured a multiple award Indefinite Delivery Indefinite Quantity, IDIQ, contract in support of the Federal Communications Commission's, FCC, requirement for application development support services. The full scope of the IDIQ includes support across program and project management, software and application development, documentation, and extreme programming for the FCC Information Technology Center. As an awardee, ECS will provide application development support services for existing, modernized, and new systems. ECS will have the dual goal of improving FCC stakeholders' experience in meeting business requirements and providing tight coordination of service delivery with other FCC ITC contractors.

07:54 EDT Aztec Minerals closes oversubscribed $3.4M private placement - Aztec Minerals announces that it has closed its oversubscribed CAD$3.4 million non-brokered private placement equity financing. The private placement consisted of 11.4 million units priced at CAD$0.30 per unit for gross proceeds of CAD$3.4 million. The Offering was first announced in the Company's press release dated May 16, 2022 for gross proceeds of up to CAD$3 million. Each unit consisted of one common share in the capital of the Company and one warrant which is exercisable to purchase an additional common share at an exercise price of CAD$0.40 per common share until June 6, 2024. Alamos Gold participated in the Offering with a subscription for 7,926,089 Units, for aggregate consideration of CAD$2,377,826.70. Prior to the closing of the Offering, Alamos held no common shares or warrants of Aztec. Following the closing of the Offering, Alamos holds, as of the date hereof, 7,926,089 common shares and 7,926,089 warrants, for a security holding percentage of 9.9% of the Company's shares on an undiluted basis and 18.0% on a partially diluted basis assuming the exercise of Alamos' warrants. Alamos acquired the units for investment purposes, which will be evaluated and may be increased or decreased from time to time at Alamos' discretion. Aztec intends to use the net proceeds of the Offering to conduct exploration work on its Cervantes porphyry gold-copper project in Sonora, Mexico, and its Tombstone epithermal gold-silver & CRD silver-lead-zinc-copper-gold project in Arizona, USA, as well as for general working capital purposes.

07:52 EDT Monarch gives results for drilling program for last 13 holes on McKenzie Break - Monarch Mining is pleased to report the results for the last 13 holes of its 2021 drilling program on the McKenzie Break deposit, located 25 kilometres north of the Corporation's wholly owned 750 tonne-per-day Beacon mill. The 2021 drilling program consisted of 54 holes for a total of 18,632 metres. Earlier results were reported on December 2, 2021 , October 20, 2021 , June 22, 2021 and March 22, 2021.The 2021 drilling program was a surface program aimed at continuing to expand the McKenzie Break gold deposit and supplementing the recent mineral resource estimate with holes drilled on 50-metre centres down to a vertical depth of 400 metres. Based on recent results outside the 2021 MRE envelope, the current program has succeeded in expanding the gently dipping deposit, particularly to the northeast. The mineralized footprint now measures 600 metres by 1,100 metres and has been tested to a vertical depth of up to 400 metres. The 2021 program also confirmed that the mineralization is continuous and remains open in all directions. The 2022 drilling program on the McKenzie Break property, which began in April with one drill rig, consists of 20,000 metres of drilling in 65 holes. A second drill rig will be added once Monarch's Swanson 10,000-metre drilling program is complete. Monarch will continue testing the deposit with holes at 50-metre centres. The 2022 program is aimed at expanding the current underground resource to the north and east, increasing the size of the currently proposed resource pit shell up-dip through expansion to the south and west and testing additional exploration targets along the volcanic-intrusive contact to the south. Later this year, Monarch will update the mineral resource estimate to include the additional 18,632 metres drilled in 2021 and several strategic holes to be drilled in 2022, as well as a new interpreted geological model. "McKenzie Break continues to show strong exploration potential in all directions as we continue to encounter high-grade gold mineralization," said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. "We expect 2022 to be another busy year on McKenzie Break and are looking forward to the results of the updated mineral resource estimate later in the year."

07:50 EDT Revival Gold to vend phosphate property to Xplore Resources - Revival Gold is pleased to announce that it has reached an agreement to vend its 51% non-core holding in the Diamond Mountain phosphate project to Xplore Resources. Diamond Mountain is an advanced stage exploration project consisting of approximately 550 hectares of State claims located in Uintah County, Utah, USA. Revival Gold will receive the following as consideration for its interest in Diamond Mountain: C$250,000 cash payment on closing; C$250,000 cash payment on the first anniversary of Closing; and, 19.9% of the issued and outstanding common shares of Xplore, following a consolidation and financing completed by Xplore. Xplore is a growing new industrial minerals focused business, led by experienced management and backed by seasoned mining investors. Xplore intends to reinitiate exploration and development on the Diamond Mountain property. The property is located immediately next to the J.R. Simplot Vernal Phosphate Mine, an important domestic United State's producer of phosrock which is utilized in the manufacturing of fertilizer. Revival Gold acquired its 51% interest in Diamond Mountain for exploration expenditures totaling approximately C$1.2 million through a joint venture earn-in agreement with Utah Minerals LLC in December 2014. The purchase of Diamond Mountain is subject to Xplore's completion of a minimum C$5 million financing, customary closing conditions and receipt of all necessary regulatory approvals, including TSX Venture Exchange approval. Closing is expected by the end of June 2022.

07:48 EDT Draganfly announces new long range LiDAR System - Draganfly is pleased to announce the launch of its new North American-made Long Range Light Detection and Ranging system. Draganfly's Long Range LiDAR system is able to provide accurate distance measurements and improved resolution over conventional photogrammetry methods. With a scanning range of 750 meters, the Company's system is able to produce 0.5-centimeter point cloud precision with two-centimeter global accuracy, which ensures high-resolution data at two million points per second.

07:47 EDT Dave & Buster's jumps 5% to $39.20 per share after Q1 earnings beat

07:43 EDT Exela Technologies announces $19M, 5-Year renewal with Irish bank - Exela Technologies announced a 5-year renewal with a leading Irish bank that began in 2013. The renewal augments an existing XBP relationship which is part of the ITPS segment. While Exela remains a leading provider of check processing to the Irish banking sector, the renewal enables the bank to embrace the entire XBP suite including robust liquidity solutions, improved communication with clients and faster transaction processing. The Total Contract Value is $19 M. "We are proud to expand our XBP penetration and renew with this leading bank. Ireland has been a strategic focus for us and we continue to invest in the region and consider it to be a blueprint for other European countries," said Vitalie Robu, President of Exela EMEA.

07:40 EDT Brooklyn ImmunoTherapeutics announces board changes - Brooklyn ImmunoTherapeutics announced the following appointments to the Board, effective June 5, 2022: Matt Angel, Ph.D., Interim CEO of Brooklyn and Co-Founder, Chairman, President and CEO of Factor Bioscience Inc.; Gregory Fiore, Co-Founder, President, and CEO of Exacis Biotherapeutics; Nicholas Singer, Founder and Managing Member of Purchase Capital; Bill Wexler, Chairman and CEO of Homer City Holdings, LLC. Erich Mohr, Dennis Langer, Heather Redman, and Erin Enright departed the Board effective June 5, 2022.

07:38 EDT Macellum, Ancora issue letter regarding nominated directors for SpartanNash - Macellum Advisors GP and Ancora Holdings Group, who beneficially own approximately 4.5% of the outstanding common shares of SpartanNash, issued the below letter regarding their campaign to elect three independent candidates to the Company's Board of Directors at the 2022 Annual Meeting of Shareholders. The Institutional Shareholder Services has recommended that shareholders vote on the Investor Group's BLUE Proxy Card and for the election of nominees Michael Lewis and John Fleming. Egan-Jones Proxy Services, another independent proxy advisory firm, also recommended that shareholders vote to elect Investor Group nominees Jonathan Duskin, Michael Lewis and Thomas Fleming and validated its case for change.

07:35 EDT CEL-SCI presents Phase 3 multikine head & neck cancer data at ASCO - CEL-SCI Corporation announced that its abstract and poster titled "Leukocyte interleukin injection immunotherapy extends overall survival in treatment-naive low-risk locally advanced primary squamous cell carcinoma of the head and neck: The IT-MATTERS study" was presented on June 6, 2022 at the American Society of Clinical Oncology's, ASCO, 2022 ASCO Annual Meeting in Chicago, Illinois. Based on the results of this pivotal Phase 3 study, including data in the ASCO poster presentation, CEL-SCI intends to file a Biologic License Application with the U.S. Food and Drug Administration for approval of this indication. The conclusions presented in the poster are as follows: Safety results were not significantly different between treatment groups. Leukocyte Interleukin, LI neoadjuvant immunotherapy did not add excess safety issues or TEAEs. In the Randomized ITT population, early LI response decreases mortality and is prognostic/predictive of OS. ITT Lower Risk LI+CIZ+SOC absolute OS advantage over SOC alone increased over time to 14.1% at 5-years; the 0.68 HR corresponds to a 47% prolongation of median survival.

07:34 EDT Dave & Buster's provides Q2 business update - The Company's business has continued to strengthen through the first five weeks of the second quarter, during which comparable store sales increased 12.2% compared with the same period in 2019. Walk-in comparable store sales increased 17.8% while Special Event comparable store sales declined 27.9% for the five-week period compared with 2019.

07:32 EDT Jazz Pharma announces results from Phase 2/3 trial of Rylaze - Jazz Pharmaceuticals announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group, or COG, evaluating the intramuscular, or IM, administration of Rylaze, or asparaginase erwinia chrysanthemi rywn, in adult and pediatric patients with acute lymphoblastic leukemia, or ALL, and lymphoblastic lymphoma, or LBL, who have developed hypersensitivity to an E. coli-derived asparaginase. These results will be presented as an oral presentation today at the American Society of Clinical Oncology, or ASCO, 2022 Annual Meeting. These results confirm the interim trial analysis presented in December 2021 at the 63rd American Society of Hematology Annual Meeting, and demonstrated that greater than or equal to90% of patients in Cohort 1c receiving the IM dosing regimen of 25/25/50 mg/m2 administered Monday/Wednesday/Friday achieved nadir serum asparaginase activity levels greater than or equal to0.1 IU/mL at 48 and 72 hours, with a safety profile consistent with what has been described for other asparaginases.

07:31 EDT W.P. Carey announces recent investments totaling $400M - W. P. Carey announced that since the end of the first quarter it has entered into investments totaling approximately $400M. This includes investments totaling approximately $168M under binding agreements and expected to close in 2022, with the significant majority expected to close by the end of July, subject to certain customary closing conditions. The investments advance the company's external growth strategy and in line with its diversified approach, include investments in industrial, grocery and lab properties located in the US and Europe.

07:29 EDT Target plunges 8% after announcing plans to reduce excess inventory

07:26 EDT Concert announces publication of data from Phase 2 trial of CTP-543 - Concert Pharmaceuticals announced the publication of safety and efficacy data from the randomized, double-blind, placebo-controlled dose-ranging Phase 2 clinical trial for CTP-543 in the Journal of the American Academy of Dermatology, JAAD. CTP-543 is an investigational oral Janus Kinase inhibitor being evaluated in ongoing clinical trials for the treatment of adults with moderate to severe alopecia areata, an autoimmune disease in which the immune system attacks hair follicles and results in hair loss. The publication reports clinically meaningful and statistically significant scalp hair regrowth after 24 weeks of treatment with CTP-543 in both the 8 mg twice-daily and 12 mg twice-daily dose groups in patients with alopecia areata. The publication highlights the establishment of two doses of CTP-543 with statistically significant hair regrowth and a generally well tolerated safety profile in patients with moderate to severe alopecia areata. Additionally, patient-reported outcomes of improvement following treatment with CTP-543 were statistically significant. The clinical results observed in the trial supported the Breakthrough Therapy designation from the U.S. Food and Drug Administration and the progression of CTP-543 into the THRIVE-AA pivotal Phase 3 clinical program. The Company recently reported positive topline data from the THRIVE-AA1 trial, and topline data from the THRIVE-AA2 trial is expected in the third quarter of 2022.

07:25 EDT Osisko Mining announces results from drill program at Windfall project - Osisko Mining is pleased to provide new analytical results from the ongoing drill program at its 100% owned Windfall gold project located in the Abitibi greenstone belt, Urban Township, Eeyou Istchee James Bay, Quebec. Significant new analytical results presented below include 43 intercepts in 15 underground drill holes and 12 wedges. The infill intercepts are located inside defined January 2022 mineral resource estimate blocks. The expansion intercepts are located outside the January 2022 MRE blocks and either expand resource wireframes or are in a defined zone or corridor but do not yet correlate to a specific wireframe. Osisko Chief Executive Officer John Burzynski commented: "Lynx continues to return wide high-grade intercepts which will be included in the upcoming feasibility study. Our headline hole, with an estimated true thickness of eight meters, and other holes with sub-intervals over a kilogram of gold per tonne, demonstrate the robust nature of the high-grade areas in the Lynx 4 and Triple Lynx zones." Selected high-grade intercepts include: 293 g/t Au over 11.0 metres in OSK-W-22-2605-W6, 199 g/t Au over 2.9 metres in OSK-W-22-2587-W6; 24.3 g/t Au over 13.4 metres in OSK-W-22-2587-W5; 73.4 g/t Au over 2.3 metres in WST-22-1041B and 54.9 g/t Au over 3.0 metres in WST-22-1046B.

07:24 EDT Callon Petroleum advances Permian Basin natural gas offtake strategy - As part of its operational update press release last night, Callon Petroleum stated: "The Company has advanced its natural gas offtake strategy in the Permian Basin and recently entered into multiple agreements for firm transportation to the Gulf Coast for approximately 75,000 MMBtu/d which are expected to be in effect beginning in mid-2023. Callon plans to use this capacity for its 'take-in-kind' residue gas volumes, providing additional flow assurance and reduced pricing exposure to Waha basis."

07:24 EDT Kiromic BioPharma expands Gamma Delta T cell product pipeline - Kiromic BioPharma announces it has entered into a sponsored research agreement, SRA, with Principal Investigator James Welsh, M.D. of The University of Texas MD Anderson Cancer Center. Under the two-year SRA, in vivo preclinical data will be generated from Kiromic's Gamma Delta T cell, GDT, allogeneic therapies. This SRA is intended to evaluate efficacy and patient safety outcomes to support three new investigational drug, IND, applications to the U.S. Food and Drug Administration, FDA. "We believe that the SRA will enable us to generate key in vivo data efficiently and swiftly that will demonstrate the synergistic advantages of our Gamma Delta T cell therapies in combination with existing anticancer treatment modalities. These submissions will expand the total number of our product candidate therapies to five. The first of these three new IND submissions - the Deltacel - is expected to be submitted during the second half of the year," stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. "Importantly, we expect to begin the activation of the Deltacel clinical trial by the end of this year. We believe utilizing non-genetically engineered Gamma Delta T cells as our first-in-human study is ideal to establish the tolerability and safety of our proprietary allogeneic cell therapy platform." In addition to Deltacel/KB-GDT - Kiromic's non-engineered Gamma Delta T cells that are expanded, enriched and activated through a proprietary method - the second IND is expected to focus on Procel/KB-PD1, a genetically engineered product candidate targeting PD-L1+ tumors. The third IND is expected to focus on Isocel/KB-ISO, a genetically engineered product candidate targeting mesothelin isoform 2+ tumors. This isoform of mesothelin is a tumor-specific target identified by Kiromic's proprietary DIAMOND AI bioinformatics platform.

07:22 EDT CynergisTek announces six-figure extension contract with pediatric healthcare - CynergisTek announces a six-figure extension contract for a west coast pediatric healthcare system for risk assessment, promoting interoperability security controls assessment, vendor security management, and incident response readiness services. Healthcare organizations are becoming increasingly aware of the need to ensure greater due diligence in understanding their security posture and risks faced across the enterprise. This client continues to rely on CynergisTek's expertise and array of capabilities to assist in managing risk. "Understanding cybersecurity risk to an organization is a critical and a necessary part of ensuring the impacts of disruptive cyber-attacks are minimal," said Dave Bailey, Vice President of Security Services at CynergisTek. "Proactive risk assessment and risk management help build resilient and effective safeguards," he adds.

07:18 EDT Orion Group expands commercial landscaping services with new partnership - Orion Group, a commercial facility services platform backed by Alpine Investors, announced that it has partnered with LandCare Management, a leading commercial landscaping services company based in Denver, Colorado. LandCare Management is Orion's second partner in the commercial landscaping industry. "We are excited to combine our resources with their operational expertise to accelerate LandCare's growth and continue expanding the Orion platform," said Nate Carlson, CEO of Orion Group Landscaping.

07:17 EDT Athira Pharma announces formation of Scientific Advisory Board - Athira Pharma announced the formation of a Scientific Advisory Board comprised of renowned leaders in neurology and neurodegenerative disease research - Drs. John Olichney, Anton Porsteinsson, Marwan Sabbagh, Lon Schneider, Pierre Tairot and Paul Winner. The SAB, chaired by Athira Chief Medical Officer, Dr. Hans Moebius, will offer expert scientific and clinical perspectives to guide the ongoing development of Athira's pipeline of novel, small molecule compounds. Athira's SAB members are: John Olichney, M.D., Professor of Neurology at the University of California, Davis, is an internationally recognized Alzheimer's disease and dementia researcher with expertise in electrophysiology. He directs the Cognitive Electrophysiology and Neuroimaging Lab at the Center for Mind and Brain and the Clinical Trials Unit of the UC Davis ADRC. Anton Porsteinsson, M.D., The William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine and the Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program in Rochester, N.Y., is a renowned investigator for Alzheimer's disease prevention and treatment clinical trials. Marwan Sabbagh, M.D., Professor of Neurology in the Alzheimer's and Memory Disorders Program at Barrow Neurological Institute in Phoenix, Arizona is an established investigator for Alzheimer's disease clinical trials and is currently the editor-in-chief of Neurology and Therapy. Lon Schneider, M.D., Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of University of Southern California, and the Della Martin Chair in Psychiatry and Neuroscience. Pierre Tariot, M.D., Director of the Banner Alzheimer's Institute in Phoenix, Arizona and Research Professor of Psychiatry at the University of Arizona College of Medicine, is an experienced clinician, researcher, and leader with a special emphasis on design and implementation of clinical trials. Paul Winner, D.O., FAAN, Senior Director of Premiere Research Institute, Director of Palm Beach Memory Disorder Center, Clinical Professor of Neurology Nova Southeastern University Fort Lauderdale, Florida.

07:16 EDT Novavax trading halted, news pending

07:16 EDT Ginkgo Bioworks, Novo Nordisk to partner on expression systems - Ginkgo Bioworks (DNA) announced a collaboration with Novo Nordisk (NVO) to create novel expression hosts for pharmaceutical products. Using synthetic biology, Ginkgo and Novo Nordisk will collaborate to unlock the potential of expression systems, which may accelerate and enhance the discovery and development of Novo Nordisk's biological medicines. Under the terms of the partnership, Ginkgo and Novo Nordisk will launch a multi-year collaboration. Ginkgo will receive an upfront R&D fee and is eligible to receive milestone payments as the parties advance in the collaboration.

07:16 EDT Editas, Immatics in pact to combine gamma-delta t cell therapy, gene editing - Immatics and Editas Medicine announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine's CRISPR technology and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institute's Cas9 patent estates and Broad Institute's Cas12a patent estate for human medicine By combining Editas Medicine's gene editing technology with Immatics' ACTallo allogeneic, off-the-shelf adoptive cell therapy platform based on gamma-delta T cells, gamma-delta T cells can be redirected to cancer cell targets with the goal of creating cells with enhanced tumor recognition and destruction.

07:14 EDT PharmaTher announces results from study of KETABET for depression - PharmaTher Holdings is pleased to announce results from an investigator-led observational study evaluating the impact of KETABET, a patented drug combination of FDA-approved ketamine and betaine anhydrous, on the unwanted ketamine side effects seen post ketamine treatment for subjects with depression. KETABET aims to prevent the potential adverse psychiatric effects of repeated ketamine treatment for depression and other indications, including suicidal ideation, substance abuse, post-traumatic stress disorder, and chronic pain. The investigator-led observational study is a randomized crossover study with subjects suffering from unmanageable depression and currently receiving ketamine treatment but experiencing unwanted side effects of ketamine. The study enrolled 10 subjects and aimed to determine if the administered oral betaine anhydrous before ketamine treatment can reduce some or all of the unwanted side effects observed in the first few hours of ketamine therapy as determined by the Clinician Administered Dissociative States Scale Alleviation or reduction of side effects would support further progression of this product strategy. The CADDS is currently the standard scale used for studies assessing acute psychoactive effects of ketamine. It is used to measure present-state dissociative symptoms and assess treatment-emergent dissociative symptoms. The CADDS is comprised of 23 questions each evaluated on a 5-point scaling system. Assessment is based on three components, including depersonalization, derealization and amnesia, and an overall total score representing the severity of the condition. Depersonalization is a state in which one loses a sense of identity relative to thoughts and feelings. Derealization is a state where one feels detached from their surroundings. The Study's data support the benefit of pre-treatment with oral anhydrous betaine prior to ketamine administration for certain side effects measured by CADDS, including depersonalization and derealization. A reduction in mean of 66% at 40 minutes following ketamine infusion initiation was seen for each of these measures in the Study. Ketamine and betaine were well tolerated with no serious adverse events reported. Although the Study was not meant for statistical significance, it supports the Company's planned placebo-controlled phase 2 clinical study incorporating KETABET in the Company's proprietary microneedle patch and will further evaluate betaine anhydrous dose, timing of pre-treatment, and duration of effect on depersonalization and derealization effects of low-dose ketamine. Reduction in the depersonalization and derealization side effects associated with low-dose ketamine infusion will potentially improve treatment compliance, treatment dose range, and treatment duration associated with ketamine therapy. Additional influence of pre-treatment with betaine prior to low-dose ketamine administration will further define the Company's KETABET product scope for this and potentially other indications. Complete results of the Study are expected to be submitted for presentation at a medical congress by 2H-2022. Based on the Study results, the Company is preparing to engage the FDA to establish the next steps for a planned Phase 2 clinical study to allow for KETABET evaluation in depression under the 505(b)(2) regulatory pathway. The Company intends to use its proprietary hydrogel-forming microneedle patch for the planned Phase 2 clinical study.

07:12 EDT Lantronix announces EchoNous utilizes solutions in Kosmos development - Lantronix announced that its Open-Q Micro SOM, Development Kit and Engineering Services were utilized by EchoNous in the development of Kosmos, the first AI-assisted handheld ultrasound device.

07:10 EDT Else Nutrition enters agreement with Baozun in China - ELSE NUTRITION HOLDINGS announced that Baozun, the Company expects to start selling Else products in China in Q3 of this year. With Baozun's e-commerce, end-to-end solutions, the Company would have direct access to retail buyers in China, starting in Q3 2022, through a wide range of online shopping platforms such as Tmall, JD.com, Kuaishou, WeChat Mini programs, and many others. With the recent distribution agreement signing, the Company expects to start operating on China's cross-border e-commerce platforms as early.

07:07 EDT Apellis, Sobi announce1st patient dosed in pegcetacoplan study for IC-MPGN, C3G - Apellis Pharmaceuticals, and Sobi announced that the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex membranoproliferative glomerulonephritis IC-MPGN and C3 glomerulopathy C3G, two rare and debilitating kidney diseases with similar underlying causes and no approved treatment."Individuals with IC-MPGN and C3G experience a high burden of disease due to the lack of approved treatments to slow or stop disease progression. These diseases often lead to kidney failure, requiring dialysis or a kidney transplant, imposing further substantial burdens," said Kristen Hood, MSN, RN, executive director of research engagement at Nephcure Kidney International. "We are excited that Apellis and Sobi are advancing a Phase 3 study of pegcetacoplan in patients aged 12 and older, with primary IC-MPGN or C3G, including those with post-transplant recurrence." "Sobi and Apellis are the only companies actively pursuing a treatment for IC-MPGN," said Anders Ullman, M.D., Ph.D., head of research and development and chief medical officer at Sobi. "We are pleased that the first patient has been dosed in this Phase 3 study for IC-MPGN and C3G, both of which represent an extremely high unmet medical need. We are committed to bringing a meaningful treatment to patients affected by these severe diseases."

07:05 EDT Kazia Therapeutics: Phase 2 study of paxalisib advances to expansion stage - Kazia Therapeutics is pleased to announce that a phase II, genomically-guided study of multiple therapies in patients with brain metastases, led by the Alliance for Clinical Trials in Oncology, has advanced the paxalisib arm to an expansion stage in breast cancer, following completion of the pre-specified interim analysis.

07:03 EDT J.M. Smucker sees FY23 free cash flow $500M; CapEx $550M - Sees FY23 adjusted effective tax rate 24.2%.

06:57 EDT Ferguson releases ESG report - Ferguson announced the release of its Fiscal Year 2021 Environmental, Social and Governance report. Titled "Building Influence. Delivering Impact," the report highlights Ferguson's progress in conducting its operations with a lighter footprint while creating positive impact for its stakeholders. "We are dedicated to minimizing the environmental impact of our operations and fostering a culture that is safe, inclusive and engaging for our associates," said Kevin Murphy, Ferguson CEO. "This ESG report showcases how our people, expertise and position within the value chain create positive impact opportunities for our customers, suppliers and local communities and help build a better world."

06:54 EDT TreeHouse CFO William Kelley to step down - TreeHouse Foods announced that William Kelley Jr. will step down as EVP and CFO to pursue another professional opportunity. Kelley will remain with TreeHouse through June 30, 2022 to ensure a smooth transition and will be succeeded on an interim basis by Patrick O'Donnell, Chief Accounting Officer of TreeHouse Foods. The Company has engaged an executive search firm to review candidates for a permanent CFO, including both internal and external candidates.

06:49 EDT United Natural Foods sees FY22 CapEx $250M vs. prior view of $300M

06:47 EDT Merck and Ridgeback announce additional data from Phase 3 MOVe-OUT trial - Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine has published additional data from the Phase 3 MOVe-OUT trial evaluating LAGEVRIO an investigational oral antiviral medicine, in non-hospitalized adults with mild to moderate COVID-19 who were at high risk for progressing to severe disease. Analyses of pre-specified exploratory endpoints indicate that a lower proportion of LAGEVRIO-treated participants in the modified intent-to-treat, or MITT, population had an acute care visit or a COVID-19-related acute care visit versus placebo-treated participants in the MITT population: 7.2% of participants who received LAGEVRIO reported an acute care visit through Day 29, versus 10.6% of placebo participants, with a relative risk reduction, or RRR, of 32.1%; 6.6% of participants who received LAGEVRIO reported a COVID-19-related acute care visit, versus 10.0% of placebo participants, with a RRR of 33.8%. The MITT population included all participants who were randomly assigned, received at least one dose of study drug, and were not hospitalized before the first dose of study drug. Based on a post hoc analysis, fewer LAGEVRIO-treated participants in the MITT population required respiratory interventions versus placebo-treated participants, with a RRR of 34.3% for all respiratory interventions.

06:47 EDT International Game debuts Cobalt 27 VLTs in Canada - International Game Technology announced that it will deliver 960 Cobalt 27 video lottery terminals to Manitoba Liquor and Lotteries Corporation. This marks the first installment of IGT's Cobalt VLT in Canada.

06:38 EDT Cazoo announces 15% headcount reduction and other cost reduction measures - Cazoo Group announced a business realignment plan. Whilst growth remains strong, with record retail unit sales in May, the Company is not immune to the rapid shift in the global economy and the possibility of a recession in the coming months. Considering these macroeconomic conditions, the Company is acting decisively to implement a business realignment plan to right-size the business and conserve cash in the short-term. The plan prioritises gross margin and retail GPU growth, with a focus on cash preservation, whilst delivering strong growth in retail unit sales of over 100% in 2022. Alex Chesterman OBE, Founder & CEO, commented, "The combination of rising inflation and interest rates with supply chain issues caused by the pandemic and war has driven up the cost of living and hit consumer confidence. This perfect storm has placed cash conservation top of mind for the Company, ahead of growth." The company's key goals from this plan are to: Lower selling, general and admin costs per unit while minimising the impact on growth; Achieve UK breakeven at lower retail unit sales with stronger focus on GPU and working capital; Manage costs and expenditure to become self-funding in the UK without needing further capital. Actions being undertaken to lower costs and drive operational efficiencies: Reducing existing employee headcount by c.15% and slowing the pace of new hiring, Lowering our brand marketing spend and focusing more on performance marketing; Limiting our capital expenditure and delaying a number of planned investment projects; Rationalising our vehicle preparation and customer support sites to drive more efficiency; Increasing focus on driving GPU growth through more efficient buying and reconditioning; Modifying our consumer proposition to drive costs down and improve operating efficiencies; Increasing procurement efficiencies across our entire supply chain to reduce overhead costs; Slowing our near-term growth aspirations in both the UK and EU to focus on profitable growth. The Company will no longer be offering its subscription service to new subscribers from the end of June. It is expected that the combination of these initiatives will result in cash savings to the Company's budget of over GBP 200M during the period from June 1, 2022 to December 31, 2023 with approximately 750 roles being impacted across the business. The Company will continue to evaluate its business plan as necessary to address trends in the marketplace and macroeconomic factors.

06:36 EDT Shin-Matsudo Central General Hospital selects ViewRay MRIdian system - ViewRay announced that Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy Center in Japan. This is the third MRIdian system in Japan intended to help address an unmet need with a growing population and an increasing rate of cancer patients in Toukatsu. The center expects to begin patient treatments in the early Fall of 2023. With a population of three million in the Toukatsu area, there is a potential shortage of radiation treatment facilities. The addition of a MRIdian system is intended to help address this issue by providing cutting-edge radiation to local patients. The hospital intends to utilize MRIdian's full capabilities including stereotactic body radiation therapy and hypofractionated radiation delivery, as well as on-table adaptive therapy, for various indications with an emphasis on those that require extreme precision such as pancreas, prostate, lung, and oligometastatic disease.

06:33 EDT Veru submits EUA application to FDA for sabizabulin - Veru announced that is has submitted an emergency use authorization application to the U.S. FDA for its sabizabulin oral 9mg treatment of moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome. Mitchell Steiner, M.D., Chairman, President, and CEO of Veru said, "We have also scaled up manufacturing of sabizabulin 9mg capsules to meet the needs of patients in the U.S. and are building our U.S. infectious disease commercial franchise. We look forward to working with the FDA during its review of our request for EUA application. We have also begun seeking EUA and approvals with other regulatory agencies around the world."

06:31 EDT Annexon announces data from Phase 2 clinical trial of ANX005 - Annexon announced promising, final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington's disease, or HD. HD is a fatal, progressive movement disorder that affects approximately 80,000 people globally, with about 300,000 people who are at-risk of inheriting the disease-causing gene. Annexon's unique approach to tackle HD targets C1q, the initiating molecule of the classical complement pathway, to slow or halt classical complement diseases. In neurodegenerative diseases like HD, C1q inappropriately recognizes and tags functioning synapses necessary for normal brain health by activating and amplifying complement components that cause neuroinflammation, synapse damage and ultimately synapse loss. ANX005 is designed to fully block C1q and the entire classical complement pathway with the aim of preserving functioning synapses to slow or halt neurodegeneration.

06:27 EDT Franchise Group to contribute $1B to Kohl's transaction upon definitive deal - In a separate press release last night confirming three-week exclusive negotiations with Kohl's (KSS), Franchise Group (FRG) stated: "Franchise Group announced that it has entered into a three week exclusive negotiation period to acquire Kohl's Corporation for $60.00 per share in cash. If Franchise Group and Kohl's Corporation enter into a definitive agreement, Franchise Group intends to contribute approximately $1 billion of capital to the transaction, all of which is expected to be funded through a corresponding increase in the size of its secured debt facilities. A majority of the financing for the transaction is anticipated to be provided on the basis of the real estate assets of Kohl's Corporation. Other than the increased secured debt facilities of Franchise Group, none of the financing for the transaction is expected to be recourse to Franchise Group. Franchise Group remains committed to its conservative financial policies, including target leverage levels, and maximizing free cash flow generation. If a transaction is completed, it is anticipated that the free cash flow, Adjusted EBITDA and Non-GAAP EPS of Franchise Group would significantly increase. The significant increase in free cash flow generation is expected to further Franchise Group's objective of increasing dividends and other capital return to shareholders, while also enabling Franchise Group to accelerate continued organic and inorganic investments."

06:14 EDT Snow Lake Lithium collaborates with University of Manitoba - Snow Lake Resources announced the collaboration with the University of Manitoba to strengthen the understanding of the lithium deposits in Snow Lake and to support the development of a framework to help shape Canada's future minerals and metals strategy. With demand for electric vehicles growing rapidly, the global automotive and energy storage industries will be competing to access raw materials, especially lithium, which is a crucial component of batteries. As a global mining powerhouse, Canada is perfectly placed to meet this increasing global demand for critical minerals such as lithium. Led by Dr. Mostafa Fayek from the University's Faculty of Environment, Earth and Resources, the two-year research project between Snow Lake Lithium and the University of Manitoba will provide considerable insights into the Company's critical mineral inventory and most effective exploration strategies to extract lithium from the Company's Snow Lake Lithium site in the future. Based in Manitoba, Canada, Snow Lake Lithium is developing the world's first all-electric lithium mine to enable domestic supply of this critical resource to the North American electric vehicle industry. Snow Lake Lithium is ideally located to serve the North American automotive industry with access to the US rail network via the Artic Gateway railway, which reduces transportation from thousands of miles by road and boat to just several hundred by train. Snow Lake Lithium's 55,000-acre site is expected to produce 160,000 tonnes of 6% lithium spodumene a year over a 10-year period. Currently, Snow Lake Lithium has explored around 1% of its site and is confident that further exploration will increase estimates over the course of the next year. Snow Lake Lithium's mine will be operated by almost 100% renewable, hydroelectric power to ensure the most sustainable manufacturing approach. Over the coming months, Snow Lake Lithium will continue its engineering evaluation and drilling program across its Snow Lake Lithium Project site, with the expectation that mining operations will transition to commercial production in late 2024.

06:11 EDT Real Good Food announces launch of chicken enchiladas in Sam's Club - The Real Good Food Company has announced the launch of its newest product, Grande Chicken Enchiladas, in Sam's Club stores nationwide. Real Good Foods is building on momentum in Sam's Club stores after launching two products earlier this year.

06:07 EDT Augusta Gold announces results of mineral resource estimate at Reward Project - Augusta Gold Corp. (TSX: G) (OTCQB: AUGG) (FSE:11B) ("Augusta Gold" or the "Company") is pleased to announce the results of its mineral resource estimate at the Reward Project located in Nevada, USA. Closing of the Company's acquisition of the Reward Project is expected imminently. Highlights: Reward: measured and indicated mineral resources of 426,700 oz gold grading 0.75 g/t gold and inferred mineral resources of 27,100 oz gold grading 0.68 g/t gold; fully permitted, low-risk heap leach project; ample water rights and sufficient water supply in place. Bullfrog: measured and indicated mineral resource estimate of 1,209,290 oz gold grading 0.53 g/t gold and combined inferred mineral resources of 257,900 oz gold grading 0.48 g/t gold; completing required studies for Mine Plan of Operation scheduled for submission H1 2023. Reward and Bullfrog: combined measured and indicated mineral resources of 1,635,990 oz gold grading 0.59 g/t gold and combined inferred mineral resources of 285,000 oz gold grading 0.50 g/t gold; Reward and Bullfrog are only 7 miles apart and located in Nevada, a top mining jurisdiction; shared infrastructure expected to provide meaningful synergies. Don Taylor, President and CEO commented: "Reward is a fully permitted, low-risk heap leach project located in a top mining jurisdiction. The recently completed pit constrained resource is indicative of what we can expect in terms of production from the property. In tandem with our work at Reward we will be completing the required studies for a Mine Plan of Operations for the Bullfrog project scheduled for submission to the regulatory agencies by H1 2023 requesting permits to begin mining operations. It is anticipated that Reward will be the first production in the district followed by the larger planned production from Bullfrog."

06:03 EDT Global Consumer Acquisition to extend deadline for business combination - Global Consumer Acquisition Corp. announced that, on June 6, it notified the trustee of the company's trust account of its intent to extend the time available to the company to consummate a business combination from June 11 to September 11. The Extension is the first of up to two three-month extensions permitted under GACQ's governing documents. In connection with such Extension, Global Consumer Acquisition LLC, the company's sponsor, will deposit an aggregate of $1,826,300 into GACQ's trust account prior to June 11, on behalf of the company. GACQ will issue a press release the day after the applicable deadline announcing that the funds have been timely deposited. The Extension provides GACQ with additional time to complete its proposed business combination with GP Global Limited and Luminex Home Decor & Fragrance Holding Corporation, industry leaders in branded, licensed and private label solutions in the Air Care and Personal Care sectors.

06:01 EDT Biodesix obtains Medicare coverage for Nodify CDT lung nodule test - Biodesix announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix's De Soto, Kansas laboratory, has provided coverage for the Nodify CDT lung nodule test. The Nodify CDT test is a part of the Biodesix's blood-based Nodify Lung Nodule Risk Assessment testing strategy consisting of two tests to aid physicians in stratifying patients into distinct nodule management treatment pathways: diagnostic procedure or imaging surveillance. The Nodify CDT test helps identify patients with lung nodules that are likely malignant or higher risk of cancer, and the Nodify XL2 test conversely helps identify those that are likely benign or lower risk of cancer.

05:55 EDT Hello Group reports MAUs of 110.9M in March vs. 115.3M a year ago - MAU on Tantan application were 25.6M in March 2022. Total paying users of live video service and value-added service, without double counting the overlap and including 2.4M paying users of Tantan Limited, were 11M for the first quarter of 2022, compared to 12.6M for the first quarter of 2021, which included 3.5M paying users of Tantan.

05:52 EDT Eli Lilly reports new findings from Phase 3 study of lebrikizumab - Eli Lilly and Company announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company's investigational IL-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis. The new findings from the Phase 3 clinical trials showed eight out of ten patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with the once every two weeks or four weeks regimen. Additionally, patients treated with lebrikizumab maintained itch relief across the two trials over the one-year period. These results build upon positive data from the 16-week, double-blind, placebo-controlled part of the ADvocate program. In ADvocate 1, 79% of patients who received lebrikizumab every four weeks and 79% of patients who received lebrikizumab every two weeks maintained 75% or greater skin improvement at one year of treatment. Additionally, 85% of patients who received lebrikizumab every four weeks and 77% of patients who received lebrikizumab every two weeks maintained EASI-75 response in ADvocate 2 at one year of treatment. The frequency of adverse events and the overall safety profile among these patients treated with lebrikizumab were consistent with the induction phase of the trials as well as previous lebrikizumab studies in AD. No new safety signals were observed in this patient population. With these data, Lilly plans to submit a Biologics License Application to the U.S.FDA for lebrikizumab in AD in the second half of 2022, followed by submissions to other regulatory agencies around the world. Almirall also plans to submit these results this year to the European Medicines Agency for authorization.